OVID THERAPEUTICS INC., 10-Q filed on 5/12/2026
Quarterly Report
v3.26.1
Cover Page - shares
3 Months Ended
Mar. 31, 2026
May 08, 2026
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2026  
Document Transition Report false  
Entity File Number 001-38085  
Entity Registrant Name Ovid Therapeutics Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 46-5270895  
Entity Address, Address Line One 441 Ninth Avenue  
Entity Address, Address Line Two 14th Floor  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10001  
City Area Code 646  
Local Phone Number 661-7661  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol OVID  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   186,640,102
Entity Central Index Key 0001636651  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2026  
Document Fiscal Period Focus Q1  
Amendment Flag false  
v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 94,064 $ 13,153
Marketable securities 61,458 56,482
Prepaid expenses and other current assets 4,623 4,733
Total current assets 160,145 74,368
Marketable securities - noncurrent 10,076 20,812
Long-term equity investments 41,961 41,961
Restricted cash 1,931 1,931
Right-of-use asset, net 11,298 11,610
Property and equipment, net 217 252
Total assets 225,628 150,934
Current liabilities:    
Accounts payable 8,876 1,956
Accrued expenses 5,413 4,899
Current portion, lease liability 1,459 1,433
Total current liabilities 15,748 8,288
Long-term liabilities:    
Lease liability 11,611 11,986
Total liabilities 27,359 20,274
Stockholders’ equity:    
Common stock, $0.001 par value; 315,000,000 shares authorized; 167,266,466 and 130,184,353 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively 167 130
Additional paid-in-capital 537,225 452,445
Accumulated other comprehensive loss (422) (202)
Accumulated deficit (338,701) (321,713)
Total stockholders’ equity 198,269 130,660
Total liabilities and stockholders’ equity $ 225,628 $ 150,934
v3.26.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2026
Dec. 31, 2025
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 315,000,000 315,000,000
Common stock shares issued (in shares) 167,266,466 130,184,353
Common stock, shares outstanding (in shares) 167,266,466 130,184,353
v3.26.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue:    
Total revenue $ 0 $ 130
Operating expenses:    
Research and development 11,181 6,659
General and administrative 6,665 6,021
Total operating expenses 17,846 12,680
Loss from operations (17,846) (12,550)
Other income (expense), net 858 2,315
Loss before provision for income taxes (16,988) (10,235)
Provision for income taxes 0 0
Net loss $ (16,988) $ (10,235)
Series A Preferred Stock    
Operating expenses:    
Net loss per share, basic (in dollars per share) $ 0 $ (141.57)
Net loss per share, diluted (in dollars per share) $ 0 $ (141.57)
Weighted-average common shares outstanding, basic (in shares) 0 1,250
Weighted-average common shares outstanding, diluted (in shares) 0 1,250
Common Stock    
Operating expenses:    
Net loss per share, basic (in dollars per share) $ (0.12) $ (0.14)
Net loss per share, diluted (in dollars per share) $ (0.12) $ (0.14)
Weighted-average common shares outstanding, basic (in shares) 136,171,393 71,045,265
Weighted-average common shares outstanding, diluted (in shares) 136,171,393 71,045,265
v3.26.1
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Statement of Comprehensive Income [Abstract]    
Net loss $ (16,988) $ (10,235)
Other comprehensive loss:    
Cumulative translation adjustment (122) (11)
Unrealized loss on marketable securities (98) (2)
Comprehensive loss $ (17,208) $ (10,248)
v3.26.1
Condensed Consolidated Statements of Stockholders’ Equity (unaudited) - USD ($)
$ in Thousands
Total
Issuance of shares of common stock from sales under the ATM program, net of expenses
Issuance of shares of common stock and pre-funded warrants from private placement financing
Series A Warrants
2025 Private Placement
Series A Convertible Preferred Stock
Series A Convertible Preferred Stock
Common Stock
Common Stock
Issuance of shares of common stock from sales under the ATM program, net of expenses
Common Stock
Issuance of shares of common stock and pre-funded warrants from private placement financing
Common Stock
Series A Warrants
2025 Private Placement
Additional Paid-In Capital
Additional Paid-In Capital
Issuance of shares of common stock from sales under the ATM program, net of expenses
Additional Paid-In Capital
Issuance of shares of common stock and pre-funded warrants from private placement financing
Additional Paid-In Capital
Series A Warrants
2025 Private Placement
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024         1,250                    
Beginning balance at Dec. 31, 2024 $ 68,226       $ 0 $ 71       $ 372,489       $ (35) $ (304,299)
Beginning balance (in shares) at Dec. 31, 2024           71,009,866                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan (in shares)           99,648                  
Issuance of shares of common stock from exercise of stock options, employee stock purchase plan and vesting of RSU awards 13                 13          
Stock-based compensation expense 1,284                 1,284          
Other comprehensive loss (12)                         (12)  
Net loss (10,235)                           (10,235)
Ending balance (in shares) at Mar. 31, 2025         1,250                    
Ending balance at Mar. 31, 2025 59,276       $ 0 $ 71       373,786       (47) (314,533)
Ending balance (in shares) at Mar. 31, 2025           71,109,514                  
Beginning balance (in shares) at Dec. 31, 2025         0                    
Beginning balance at Dec. 31, 2025 $ 130,660       $ 0 $ 130       452,445       (202) (321,713)
Beginning balance (in shares) at Dec. 31, 2025 130,184,353         130,184,353                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Issuance of shares of common stock from sales under the ATM program, net of expenses (in shares)             1,500,000                
Issuance of shares of common stock from sales under the ATM program, net of expenses   $ 2,367         $ 2       $ 2,365        
Issuance of shares of common stock and pre-funded warrants from private placement financing (in shares)               19,154,321              
Issuance of shares of common stock and pre-funded warrants from private placement financing     $ 60,000         $ 19       $ 59,981      
Expenses related to the issuance of shares of common stock and pre-funded warrants     $ (3,816) $ (1,593)               $ (3,816) $ (1,593)    
Exercise of Series A warrants to shares of common stock and pre-funded warrants (in shares)                 16,140,663            
Exercise of Series A warrants to shares of common stock and pre-funded warrants       $ 26,593         $ 16       $ 26,577    
Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan (in shares)           287,129                  
Issuance of shares of common stock from exercise of stock options, employee stock purchase plan and vesting of RSU awards $ 220                 220          
Stock-based compensation expense 1,046                 1,046          
Other comprehensive loss (220)                         (220)  
Net loss (16,988)                           (16,988)
Ending balance (in shares) at Mar. 31, 2026         0                    
Ending balance at Mar. 31, 2026 $ 198,269       $ 0 $ 167       $ 537,225       $ (422) $ (338,701)
Ending balance (in shares) at Mar. 31, 2026 167,266,466         167,266,466                  
v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities:    
Net loss $ (16,988) $ (10,235)
Adjustments to reconcile net loss to cash used in operating activities:    
Unrealized loss on equity investments 0 66
Change in accrued interest and accretion of discount on marketable securities (287) (197)
Stock-based compensation expense 1,046 1,284
Depreciation and amortization expense 35 141
Noncash operating lease expense 312 288
Change in lease liability (349) (325)
Change in operating assets and liabilities:    
Prepaid expenses and other current assets 110 (60)
Accounts payable 3,624 (1,242)
Accrued expenses (1,402) (1)
Net cash used in operating activities (13,899) (10,280)
Cash flows from investing activities:    
Purchase of marketable securities (4,050) (4,898)
Sales/maturities of marketable securities 10,000 10,000
Net cash provided by investing activities 5,950 5,102
Cash flows from financing activities:    
Proceeds from issuance of shares of common stock and pre-funded warrants from PIPE financing, net of expenses 59,803 0
Proceeds from exercise of Series A warrants into shares of common stock and pre-funded warrants 26,593 0
Proceeds from sale of shares of common stock under ATM program, net of expenses 2,366 0
Proceeds from exercise of options and employee stock purchase plan 220 13
Net cash provided by financing activities 88,982 13
Effect of exchange rates on cash, cash equivalents and restricted cash (122) 0
Net increase (decrease) in cash, cash equivalents and restricted cash 80,911 (5,165)
Cash, cash equivalents and restricted cash, at beginning of period 15,084 28,232
Cash, cash equivalents and restricted cash, at end of period 95,995 23,067
Non-cash investing and financing activities:    
Banking and placement fees in accounts payable and accrued expenses $ 5,211 $ 0
v3.26.1
NATURE OF OPERATIONS
3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS NATURE OF OPERATIONS
Ovid Therapeutics Inc. (the “Company”) was incorporated under the laws of the state of Delaware, commenced operations on April 1, 2014, and maintains its principal executive office in New York, New York. The Company is a biopharmaceutical company dedicated to pioneering better, gentler small molecule medicines for brain disorders with significant unmet need. The Company is currently focused on developing OV329, OV4071 and other undisclosed potential medicines.
Since its inception, the Company has devoted substantially all of its efforts to business development, research and development, recruiting management and technical staff, and raising capital, and has financed its operations through the issuance of convertible preferred stock, common stock, other equity instruments, the sale and/or licensing of certain assets and the licensing of certain intellectual property. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development and regulatory success, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations.
The Company’s major sources of cash have been licensing revenue, proceeds from various public and private offerings of its capital stock, option exercises and interest income. As of March 31, 2026, the Company had $165.6 million in cash, cash equivalents and marketable securities. Since inception, the Company has generated its revenue primarily from the Company’s royalty, license and termination agreement (“RLT Agreement”) with Takeda Pharmaceutical Company Limited (“Takeda”). For most periods, the Company has incurred recurring losses, has experienced negative operating cash flows and has required significant cash resources to execute its business plans, which the Company expects will continue for the foreseeable future. The Company had an accumulated deficit of $338.7 million as of March 31, 2026, working capital of $144.4 million and net cash used in operating activities of $13.9 million for the three months ended March 31, 2026. The Company recorded net losses of $17.0 million and $10.2 million, respectively, during the three month periods ended March 31, 2026 and 2025, and expects to incur losses in subsequent periods for at least the next several years. The Company is highly dependent on its ability to find additional sources of funding through either equity offerings, debt financings, collaborations, strategic alliances, licensing agreements or a combination of any such transactions.
Management believes that the Company’s existing cash, cash equivalents and marketable securities as of March 31, 2026 will be sufficient to fund its current operations through at least 12 months from the date of the issuances of these unaudited interim condensed consolidated financial statements. Adequate additional funding may not be available to the Company on acceptable terms or at all. The failure to raise capital as and when needed will have a negative impact on the Company’s financial condition and ability to pursue its business strategy. If the Company is unable to raise capital on acceptable terms, the Company will be required to delay, reduce the scope of or eliminate research and development programs, or obtain funds through arrangements with collaborators or others that may require the Company to relinquish rights to certain drug candidates that the Company might otherwise seek to develop or commercialize independently.
The Company is subject to challenges and risks specific to its business and its ability to execute on its strategy, as well as risks and uncertainties common to early-stage companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: delays or problems in the supply of the Company’s product candidates; loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing intellectual property rights; complying with applicable regulatory requirements; obtaining regulatory approval of any of the Company’s potential product candidates, among others.
v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Mar. 31, 2026
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(A) Unaudited Interim Condensed Consolidated Financial Statements
The interim condensed consolidated balance sheet at March 31, 2026 and the condensed consolidated statements of operations, comprehensive loss, cash flows, and stockholders’ equity for the three months ended March 31, 2026 and 2025 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and follow the requirements of the SEC for interim reporting. As permitted under those rules, certain notes or other financial information that are normally required by GAAP are condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual financial
statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three months ended March 31, 2026 and 2025 are not necessarily indicative of the results to be expected for the year ending December 31, 2026 or for any other future annual or interim period. The balance sheet as of December 31, 2025 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements as of and for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K.
(B) Basis of Presentation and Consolidation
The accompanying interim condensed consolidated financial statements have been prepared in conformity with GAAP and include the accounts of Ovid Therapeutics Inc. and its wholly owned subsidiaries, Ovid Therapeutics Australia Pty Ltd and Ovid Therapeutics Hong Kong Ltd. All intercompany transactions and balances have been eliminated in consolidation.
(C) Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.
(D) Marketable Securities
Marketable securities consist of investments in U.S. treasury instruments which are considered available-for-sale securities. The Company classifies its marketable securities with original maturities of less than three months as cash equivalents on its condensed consolidated balance sheets. The Company classifies its marketable securities with maturities of less than one year from the balance sheet date as current assets on its condensed consolidated balance sheets. The Company classifies its marketable securities with maturities of greater than twelve months as noncurrent assets on its consolidated balance sheets. Unrealized gains and losses on these securities that are determined to be temporary are reported as a separate component of accumulated other comprehensive (loss) income in stockholders’ equity.
(E) Restricted Cash
The Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as noncurrent unless restrictions are expected to be released in the next 12 months.
(F) Long-Term Equity Investments
Long-term equity investments consist of equity investments in the preferred shares of Gensaic, Inc., formerly M13 Therapeutics, Inc. (“Gensaic”), and Graviton Bioscience Corporation (“Graviton”), both privately held corporations. The preferred shares are not considered in-substance common stock, and the investments are accounted for at cost, with adjustments for observable changes in prices or impairments, and are classified within long-term equity investments on the condensed consolidated balance sheets with adjustments recognized in other income (expense), net on the condensed consolidated statements of operations. The Company has determined that these equity investments do not have a readily determinable fair value and elected the measurement alternative. Therefore, the carrying amount of the equity investments will be adjusted to fair value at the time of the next observable price change for the identical or similar investment of the same issuer or when an impairment is recognized. Each reporting period, the Company performs a qualitative assessment to evaluate whether the investments are impaired. The assessment includes a review of recent operating results and trends, recent sales/acquisitions of the investees’ securities, and other publicly available data. If an investment is determined to be impaired, the Company will then write it down to its estimated fair value. As of March 31, 2026 and December 31, 2025, the equity investment in Gensaic had a carrying value of $5.1 million. As of March 31, 2026 and December 31, 2025, the equity investment in Graviton had a carrying value of $36.8 million. The initial investment in Graviton was $10.0 million, and cumulative measurement adjustments based on observable price increases totaling $26.8 million have been recognized, recorded in other income (expense), net within the statement of operations.
No impairments were recognized in the three month periods ended March 31, 2026 and 2025.
(G) Fair Value of Financial Instruments
Financial Accounting Standards Board (“FASB”) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest
priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).
The three levels of the fair value hierarchy are as follows:
Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company’s Level 1 assets consisted of investments in a U.S. treasury money market fund of $81.2 million as of March 31, 2026, and U.S. treasury money market funds totaling $25.8 million as of December 31, 2025.
Level 2—Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company’s Level 2 assets consisted of U.S. treasury bills, totaling $71.5 million as of March 31, 2026 and $26.8 million as of December 31, 2025.
Level 3—Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. There were no Level 3 assets as of March 31, 2026 or December 31, 2025. The Company’s Level 3 liabilities consist of a royalty monetization liability that is immaterial as of March 31, 2026 and December 31, 2025 due to the improbability that the program would be further developed into a commercial product.
The carrying amounts reported in the balance sheets for cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair values based on the short-term maturity of these instruments.
(H) Leases
The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with FASB Accounting Standards Codification (“ASC”) 842. Operating leases are included in right-of-use (“ROU”) assets, current liabilities, and long-term lease liability in the Company’s condensed consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.
(I) Property and Equipment
Property and equipment are stated at cost and depreciated over their estimated useful lives of three years using the straight-line method. Repair and maintenance costs are expensed. The Company reviews the recoverability of all long-lived assets, including the related useful life, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable.
(J) Royalty Monetization Liability
The Company accounted for its sale to Ligand Pharmaceuticals Incorporated (“Ligand”) of a 13% share of royalties and milestones owed to the Company related to the potential approval and commercialization of soticlestat (“Ligand Agreement”) in accordance with ASC 470, Debt, classifying the proceeds received from the sale to Ligand as debt as the Company determined that it had significant continuing involvement in the generation of the cash flows to Ligand. The Company further elected to account for the debt at fair value with changes in the fair value of the debt classified as other income (expense) in the consolidated statements of operations. In June 2024, Takeda issued a press release indicating the soticlestat trials missed their primary endpoints and noted that while Takeda would discuss the program with the FDA, Takeda fully impaired the asset representing soticlestat. In January 2025, Takeda announced the discontinuation of the program.
(K) Research and Development Expenses
The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as contracted services, license fees, and other external costs. Research and development expenses also include the cost of licensing agreements acquired from third parties.
Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received in accordance with ASC 730, Research and Development.
(L) Stock-Based Compensation
The Company accounts for its stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation, which establishes accounting for stock-based awards granted for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company estimates the fair value of all option awards granted using the Black-Scholes valuation model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk-free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require judgment and any changes could have an impact in the determination of stock-based compensation expense. The Company elected an accounting policy to record forfeitures as they occur. The Company recognizes stock-based compensation expense based on the fair value of the award on the date of the grant. The compensation expense is recognized over the vesting period under the straight-line method. The Company aggregates employee and nonemployee awards for certain disclosures since nonemployee awards are not material.
(M) Income Taxes
The Company accounts for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as for net operating loss carryforwards and research and development credits. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The impact of a change in the tax laws is recorded in the period in which the law is enacted.
(N) Net Loss per Share
The rights and preferences of the non-voting Series A convertible preferred stock (“Series A Preferred Stock”) are negligible relative to common stock, therefore the Series A Preferred Stock is treated as in-substance common stock on an as-converted basis when allocating net loss to actual and in-substance shares of common stock. The Company applies the two-class method to allocate earnings between common stock, Series A Preferred Stock, and other securities deemed in-substance common stock and participating securities, if any. Pre-funded warrants to purchase shares of common stock (the “Pre-Funded Warrants”) are included in the number of weighted-average shares of common stock outstanding for net loss per share calculations.
Net loss per share of common stock is determined by dividing net loss attributable to common stockholders by the basic weighted-average shares of common stock outstanding during the period. Net loss per diluted share attributable to common stockholders adjusts the basic earnings per share attributable to common stockholders and the weighted-average number of shares of common stock outstanding for the potential dilutive impact of stock options, warrants, and restricted stock units (“RSUs”) using the treasury-stock method and the potential impact of any preferred stock using the if-converted method. Net loss per diluted share attributable to common stockholders omits the inclusion of stock options, common stock issuable upon conversion of Series A Preferred Stock, warrants (except the Pre-Funded Warrants) and unvested RSUs, as these securities would be anti-dilutive.
(O) Retirement Plan
The Company maintains a 401(k) retirement plan for its employees that is intended to qualify under Sections 401(a) and 501(a) of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Company provides all active employees with a 100% matching contribution equal to 3% of an employee’s eligible deferred compensation and a 50% matching contribution on employee contributions that are between 3% and 5% of an employee’s eligible deferred compensation. These safe harbor contributions vest immediately. For the three months ended March 31, 2026 and 2025, the Company contributed $66,000 and $74,000, respectively.
(P) Revenue Recognition
Under ASC 606, Revenue from Contracts with Customers, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services the
Company transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.
Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.
If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.
Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered. The Company defers recognition of upfront license fees until the performance obligations are satisfied.
(Q) Segment Reporting
Under Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): “Improvements to Reportable Segment Disclosures” (“ASU 2023-07”), the Company discloses significant segment expenses regularly provided to the chief operating decision maker (“CODM”) and discloses the title and position of the CODM.
(R) Common and Pre-Funded Warrants
The Company has issued freestanding warrants to purchase shares of its common stock in connection with financing activities and accounts for them in accordance with applicable accounting guidance as either liabilities or as equity instruments depending on the specific terms of the underlying warrant agreements. The Company has issued Pre-Funded Warrants in connection with financing activities and common warrant exercises and accounts for them as equity instruments in accordance with applicable accounting guidance.
(S) Recent Accounting Pronouncements
The Company has reviewed recently issued accounting standards and plans to adopt those that are applicable. The Company does not expect the adoption of those standards to have a material impact on its financial position, results of operations or cash flows.
In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, (“ASU 2023-09”), which is effective for annual periods beginning after December 15, 2024. ASU 2023-09 intends to enhance the transparency as well as usefulness of income tax disclosures, primarily related to the rate reconciliation and income taxes paid. The Company has implemented ASU 2023-09 retrospectively for years ended December 2024 and 2025, as reported in the Company’s Annual Report on Form 10-K for the period ending December 31, 2025.
In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires the disaggregation of certain expense captions into specified categories in disclosures within the notes to the consolidated financial statements to provide enhanced transparency into the expense captions presented on the face of the statements of income and comprehensive income. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, with early adoption permitted, and may be applied either prospectively or retrospectively to financial statements issued for reporting periods after the effective date of ASU 2024-03 or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its related disclosures.
The Company adopts new pronouncements relating to GAAP applicable to the Company as they are issued, and based upon the effective dates included in the pronouncements. Management does not believe that any recently issued, but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements.
v3.26.1
CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES
3 Months Ended
Mar. 31, 2026
Cash and Cash Equivalents [Abstract]  
CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES
The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of March 31, 2026 and December 31, 2025:
March 31, 2026
(in thousands)Amortized CostGross Unrealized Holding GainsGross Unrealized Holding LossesFair Value
Cash$12,885 $— $— $12,885 
Cash equivalents81,178 — — 81,178 
Marketable securities71,651 — (116)71,535 
Total cash, cash equivalents and marketable securities$165,714 $— $(116)$165,598 
December 31, 2025
(in thousands)Amortized CostGross Unrealized Holding GainsGross Unrealized Holding LossesFair Value
Cash$516 $— $— $516 
Cash equivalents12,636 — 12,637 
Marketable securities77,315 — (21)77,294 
Total cash, cash equivalents and marketable securities$90,467 $$(21)$90,447 
The Company did not hold any securities that were in an unrealized loss position for more than 12 months as of March 31, 2026 and December 31, 2025.
There were no material realized gains or losses on available-for-sale securities during the three months ended March 31, 2026 and 2025.
v3.26.1
PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS
3 Months Ended
Mar. 31, 2026
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS
Property and equipment is summarized as follows:
(in thousands)March 31,
2026
December 31,
2025
Furniture and equipment$1,534 $1,534 
Leasehold improvements306 306 
Less accumulated depreciation(1,623)(1,588)
Total property and equipment, net$217 $252 
Depreciation expense was $35,000 and $87,000 for the three months ended March 31, 2026 and 2025, respectively.
Intangible assets, net of accumulated amortization, were $0 and $38,000 as of March 31, 2026 and December 31, 2025, respectively, and are included in other noncurrent assets on the condensed consolidated balance sheets. Amortization expense was $0 and $53,000 for the three months ended March 31, 2026 and 2025, respectively.
v3.26.1
LEASES
3 Months Ended
Mar. 31, 2026
Leases [Abstract]  
LEASES LEASES
In September 2021, the Company entered into a 10-year lease agreement for its corporate headquarters with a term commencing March 10, 2022, for approximately 19,000 square feet of office space at Hudson Commons in New York, New York. The lease provides for monthly rental payments over the lease term. The base rent under the lease is currently $2.3 million per year. Rent payments commenced in January 2023, and continue for 10 years following the rent commencement date. The Company issued an irrevocable letter of credit in the amount of $1.9 million in association with the execution of the lease agreement; the letter of credit is characterized as restricted cash on the Company’s condensed consolidated balance sheets.
The Hudson Commons lease has a remaining lease term of approximately six years and includes a single renewal option for an additional five years. The Company did not include the renewal option in the lease term when calculating the lease liability as the Company is not reasonably certain that it will exercise the renewal option. The present value of the lease payments was calculated using an incremental borrowing rate of 7.02%. Lease expense is included in general and administrative and research and development expenses in the condensed consolidated statements of operations.
ROU asset and lease liabilities related to the Company’s operating lease are as follows:
(in thousands)March 31,
2026
December 31,
2025
ROU asset, net$11,298 $11,610 
Current lease liability1,459 1,433 
Long-term lease liability11,611 11,986 
The components of operating lease cost for the three months ended March 31, 2026 were as follows:
(in thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Operating lease cost$542 $542 
Variable lease cost— — 

Future minimum commitments under the non-cancelable operating lease are as follows:
(in thousands)
2026$1,737 
20272,316 
20282,469 
20292,469 
20302,469 
Thereafter4,939 
$16,399 
v3.26.1
ACCRUED EXPENSES
3 Months Ended
Mar. 31, 2026
Payables and Accruals [Abstract]  
ACCRUED EXPENSES ACCRUED EXPENSES
Accrued expenses consist of the following:
(in thousands)March 31,
2026
December 31,
2025
Banking and placement fees$1,916 $— 
Payroll and bonus accrual822 3,106 
Research and development accrual1,537 1,191 
Professional fees accrual703 350 
Accrued taxes169 142 
Other266 110 
Total$5,413 $4,899 
v3.26.1
STOCKHOLDERS’ EQUITY
3 Months Ended
Mar. 31, 2026
Equity [Abstract]  
STOCKHOLDERS’ EQUITY STOCKHOLDERS’ EQUITY
The Company’s capital structure consists of common stock and preferred stock. Pursuant to the Company’s amended and restated certificate of incorporation, as amended, the Company is authorized to issue up to 315,000,000 shares of common stock and 10,000,000 shares of preferred stock. The Company has designated 10,000 of the authorized shares of preferred stock as non-voting Series A convertible preferred stock (“Series A Preferred Stock”), of which none were issued and outstanding as of March 31, 2026. An additional 57,722 of the authorized shares of preferred stock are
designated as non-voting Series B convertible preferred stock (“Series B Preferred Stock”), of which none were issued and outstanding as of March 31, 2026.
The holders of common stock are entitled to one vote for each share held. The holders of common stock have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such shares. Subject to preferences that may apply to any outstanding series of preferred stock, holders of the common stock are entitled to receive ratably any dividends declared on a non-cumulative basis. The common stock is subordinate to all series of preferred stock with respect to rights upon liquidation, winding up and dissolution of the Company. The holders of common stock are entitled to liquidation proceeds after all liquidation preferences for the preferred stock are satisfied.
There were no shares of Series A Preferred Stock outstanding as of March 31, 2026 and December 31, 2025, following an optional conversion into 1,250,000 shares of common stock in December 2025. Each share of Series A Preferred Stock was convertible into 1,000 shares of common stock at any time at the holder’s option. Holders of Series A Preferred Stock were entitled to receive dividends paid to holders of common stock at an equal rate, in the same form, and in the same manner on an as-if-converted basis.
October 2025 Private Placement
In October 2025, the Company entered into a Securities Purchase Agreement with the purchasers named therein (the “2025 Investors”), pursuant to which the Company issued and sold an aggregate of (i) 57,722 shares of Series B Preferred Stock, (ii) Series A warrants (the “Series A Warrants”) to purchase up to 38,481,325 shares of the Company’s common stock and/or Pre-Funded Warrants, and (iii) Series B warrants (the “Series B Warrants” and together with the Series A Warrants, the “Warrants”) to purchase up to 28,861,000 shares of common stock and/or Pre-Funded Warrants to the 2025 Investors in a private placement (the “2025 Private Placement”). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 666.66 shares of common stock and/or Pre-Funded Warrants (rounded down to next whole share based on each such Investor’s aggregate purchase) and a Series B Warrant to purchase 500 shares of common stock and/or Pre-Funded Warrants (together, one “Security”). The Securities were sold at a purchase price of $1,400.00, which included the purchase of 71 shares of Series B Preferred Stock, 47,333 Series A Warrants, and 35,500 Series B Warrants by the Company’s Executive Chairman, which was approved by the Company’s stockholders at a special meeting in December 2025 (the “Special Meeting”).
Each share of Series B Preferred Stock converted into 1,000 shares of common stock upon receipt of stockholder approval at the Special Meeting of an increase of sufficient authorized shares of common stock to enable issuance of common stock on conversion of all of the Series B Preferred Stock. The Series B Preferred Stock is non-voting, except for customary protective provisions, and has rights to receive dividends pari passu, on an as-converted basis, if and when the shareholder of common stock received dividend payment. The Series B Preferred Stock has a liquidation preference equal to the greater of (a) $1,400.00 per share plus any declared but unpaid dividends due to stockholders of Series B Preferred Stock or (b) the amount due on an as-converted basis while maintaining the seniority of the stock class. At March 31, 2026, there were no outstanding shares of Series B Preferred Stock.
The Warrants each have an exercise price of $1.40 per share (the “Exercise Price”). The Series A Warrants became exercisable upon stockholder approval at the Special Meeting and expired on April 17, 2026, the 30th calendar day following the date on which the Company publicly announced the clearance of the first of any investigational new drug application, clinical trial application or other foreign equivalent with respect to the clinical development of the Company’s OV4071 product candidate. In the event that beneficial ownership limitations prevent the exercise by a 2025 Investor of all or a portion of the Series A Warrants held thereby, such Investor may purchase shares of common stock up to the specified limit and, for the remainder, purchase Pre-Funded Warrants in lieu of shares of common stock. The Series A Warrants meet the requirements to be recorded in permanent equity. The Series A Warrants are entitled to dividends on an as-converted basis if and when dividends are paid to common stock; therefore the Series A Warrants meet the definition of participating securities for the purpose of computing earnings per share. As of March 31, 2026, exercise notices and $26.6 million of cash had been received representing exercise of a total of Series A Warrants to purchase 18,997,329 shares of common stock, with Series A Warrants to purchase 16,140,663 shares of common stock delivered in common shares and Series A Warrants to purchase 2,856,666 shares of common stock delivered in Pre-Funded Warrants. At April 17, 2026, the expiration date of the Series A Warrants, all Series A Warrants had been exercised, with Series A Warrants to purchase 33,597,860 shares of common stock delivered in common stock and Series A Warrants to purchase 4,883,464 shares of common stock delivered in Pre-Funded Warrants for aggregate gross proceeds of $53.9 million.
The Series B Warrants expire on October 6, 2030. In the event that the closing price of the Company’s common stock equals or exceeds 300% of the Exercise Price (subject to customary adjustments) for 20 of any 30 consecutive trading days, the Company may elect to require exercise of the Series B Warrant for cash. In the event that beneficial ownership limitations prevent the exercise of all or a portion of the Series B Warrants held thereby upon any such mandatory exercise demand, such Investor will purchase shares of common stock up to the specified limit and, for the remainder, purchase Pre-
Funded Warrants. The Series B Warrants are entitled to dividends on an as-converted basis if and when dividends are paid to common stock, therefore the Series B Warrants meet the definition of participating securities for the purpose of computing earnings per share. At March 31, 2026, no Series B Warrants had been exercised.
The Company received initial net proceeds of $75.1 million from the 2025 Private Placement, after deducting placement agent fees and offering expenses of $5.7 million. Following the exercise of all of the Series A Warrants, the Company received additional gross proceeds of approximately $53.9 million. The Company may further receive up to $40.0 million in additional gross proceeds, assuming exercise in full of the remaining outstanding Series B Warrants.
The Series A Warrants were all exercised by April 17, 2026, and the Series B Warrants are currently exercisable.
The Company initially valued the components of the Securities and allocated the issuance costs using relative fair values. The Series B Preferred Stock was valued at $1.79 per underlying common share, which was the close price of the common stock on the financing close date of October 6, 2025 due to the high probability of mandatory conversion within a short period of time.
The Series A Warrants were valued at $0.75 per share using a probability-weighted expected return method based on two different expiry periods valued using a Black-Scholes model with corresponding probability for the likelihood of each scenario and Level 3 model inputs.
The Series B Warrants were valued at $1.29 using a Monte Carlo simulation model since the timing and payoff are dependent on the Company’s trailing stock price and level 3 inputs. It is assumed that the Company would trigger a mandatory conversion at the earliest triggering event.
The following table presents the level 3 inputs used in the valuation models:
Series A WarrantsSeries B
Warrants
6-month expiry5-year expiry
Probability97.5 %2.5 %
Stock price$1.79 $1.79 $1.79 
Strike price$1.40 $1.40 $1.40 
Expected volatility115 %115 %115 %
Expected term in years0.55.0
Dividend rate— — — 
Risk-free interest rate3.81 %3.75 %3.75 %
Fair value$0.73 $1.51 $1.29 
The fair value of the Series B Preferred Stock and the associated allocation of issuance costs was recorded in temporary equity until such time as the stockholder approvals were obtained at the Special Meeting. Upon gaining stockholder approval the Series B Preferred Stock converted automatically and the temporary equity balances were moved to permanent equity. The Series A Warrants and Series B Warrants do not have features that disallowed equity treatment and were recorded at relative fair value along with the allocated issuance costs in permanent equity.
March 2026 Private Placement
On March 19, 2026, the Company entered into a Securities Purchase Agreement with the purchasers named therein (the “2026 Investors”), pursuant to which the Company issued and sold an aggregate of 19,154,321 shares of common stock at a purchase price of $2.01 per share and, in lieu of common stock, Pre-Funded Warrants to purchase up to 10,701,710 shares of common stock at a purchase price of $2.009 per Pre-Funded Warrant to the 2026 Investors in a private placement (the “2026 Private Placement”). The Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and do not expire. There are no additional rights and preferences, including voting rights,
accorded to the Pre-Funded Warrants. The net proceeds, after deducting placement agent fees and transaction costs, were $56.2 million.
Warrant and Pre-Funded Warrant Activity
The following table summarizes the number of Warrants and Pre-Funded Warrants outstanding as of March 31, 2026, the weighted average exercise price, and the aggregate intrinsic value:
Series A and Series B Warrants
Pre-Funded Warrants
Weighted Average Exercise PriceAggregate Intrinsic Value
(in thousands)
Outstanding, December 31, 2025
67,342,325 $1.40 $55,221 
Pre-Funded Warrants purchased in 2026 Private Placement
— 10,701,710 0.001 23,747 
Series A Warrants exercised into common stock
(16,140,663)— — — 
Series A Warrants exercised into Pre-Funded Warrants(2,856,666)2,856,666 0.001 6,339 
Outstanding, March 31, 2026
48,344,996 13,558,376 $1.09 $68,067 

At-the-Market Offering Program
In November 2023, the Company filed a shelf registration statement on Form S-3 (Registration No. 333-275307) that allows us to sell up to an aggregate of $250.0 million of its common stock, preferred stock, convertible debt securities and/or warrants, which includes a prospectus covering the issuance and sale of up to $75.0 million of common stock pursuant to its at-the-market (“ATM”) program. During the three months ended March 31, 2026, the Company sold 1,500,000 shares through the ATM program for net proceeds of approximately $2.4 million, after deducting sales agent fees and other offering expenses. As of March 31, 2026, the Company had approximately $72.6 million available under its ATM offering program.
Dividends
Through March 31, 2026, the Company has not declared any dividends. No dividends on the common stock shall be declared and paid unless dividends on the preferred stock have been declared and paid.
v3.26.1
STOCK-BASED COMPENSATION
3 Months Ended
Mar. 31, 2026
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
The Company’s Board of Directors adopted, and the Company’s stockholders approved, the 2017 Equity Incentive Plan (“2017 Plan”), which became effective on May 4, 2017. The initial reserve of shares of common stock issuable under the 2017 Plan was 3,052,059 shares. The 2017 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, RSU awards, stock appreciation rights, performance-based stock awards, and other forms of stock-based awards. Additionally, the 2017 Plan provides for the grant of performance cash awards. The Company’s employees, officers, directors, consultants and advisors are eligible to receive awards under the 2017 Plan. Following the adoption of the 2017 Plan, no further awards will be granted under the Company’s prior plan. Pursuant to the terms of the 2017 Plan, on each January 1st, the plan limit shall be increased by the lesser of (x) 5% of the number of shares of common stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine at its discretion. On January 1, 2026, 6,509,217 additional shares were reserved for issuance under the 2017 Plan. As of March 31, 2026, there were 7,410,779 shares of the Company’s common stock reserved and available for issuance under the 2017 Plan.
The Company’s Board of Directors adopted, and the Company’s stockholders approved, the 2017 Employee Stock Purchase Plan (“2017 ESPP”), which became effective on May 4, 2017. The initial reserve of shares of common stock issuable under the 2017 ESPP was 279,069 shares. The 2017 ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated semi-annual purchase dates. During the three months ended March 31, 2026 and 2025, 33,015 and 34,509 shares were purchased under the 2017 ESPP, respectively, and the Company recorded expense of $9,000 and $21,876, respectively. The number of shares of common stock reserved for issuance under the 2017 ESPP automatically increases on January 1 of each year, beginning on January 1, 2018 and continuing through and including January 1, 2027, by the lesser of (i) 1% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, (ii) 550,000 shares or (iii) such lesser number of shares determined by the Board of Directors. The Board of Directors acted prior to each of January 1, 2026 and
January 1, 2025 to provide that there be no increase in the number of shares reserved for issuance under the 2017 ESPP on either such date. As of March 31, 2026, there were 173,005 shares of the Company’s common stock reserved and available for issuance under the 2017 ESPP.
The Company’s Board of Directors adopted, and the Company’s stockholders approved, the 2014 Equity Incentive Plan (“2014 Plan”), which authorized the Company to grant shares of common stock in the form of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock and RSUs. The 2014 Plan was terminated as to future awards in May 2017, although it continues to govern the terms of options that remain outstanding under the 2014 Plan. No additional stock awards will be granted under the 2014 Plan, and all outstanding stock awards granted under the 2014 Plan that are repurchased, forfeited, expire or are cancelled will become available for grant under the 2017 Plan in accordance with its terms. As of March 31, 2026, options to purchase 638,844 shares of common stock were outstanding under the 2014 Plan.
Unless specified otherwise in an individual option agreement, stock options granted under the 2014 Plan and the 2017 Plan generally have a ten-year term and a four-year graded vesting period. The vesting requirement is generally conditioned upon the grantee’s continued service with the Company during the vesting period. Once vested, all options granted are exercisable from the date of grant until they expire. The option grants are non-transferable. Vested options generally remain exercisable for 90 days under the 2017 Plan and 30 days under the 2014 Plan subsequent to the termination of the option holder’s service with the Company. In the event of the option holder’s death or disability while employed by or providing service to the Company, the exercisable period extends to 18 months or 12 months, respectively, under the 2017 Plan and six months under the 2014 Plan.
The fair value of options granted during the three months ended March 31, 2026 and 2025 was estimated using the Black-Scholes option valuation model. The inputs for the Black-Scholes option valuation model require assumptions that are detailed in the table below. The risk-free interest rates are based on the rate for U.S. treasury securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life is based on the simplified method in accordance with the SEC Staff Accounting Bulletin No. Topic 14D. The expected volatility was estimated based on the Company’s published historical stock prices.
The Company granted 4,575,750 and 3,370,900 stock options during the three months ended March 31, 2026 and 2025, respectively. There were 9,136,687 and 8,299,628 unvested options outstanding as of March 31, 2026 and 2025, respectively. Total expense recognized related to the stock options for the three months ended March 31, 2026 and 2025 was $0.8 million and $1.3 million, respectively. During the three months ended March 31, 2026 and 2025, the Company had no outstanding performance-based option awards and did not record any related expense in those periods.
The Company granted 398,375 and 249,201 RSU awards during the three months ended March 31, 2026 and 2025, respectively. The RSUs vest in equal installments over three years on the grant date anniversary. At March 31, 2026, there were 669,545 RSUs outstanding. At March 31, 2026, there was $1.2 million of unrecognized stock–based compensation expense related to RSUs, which is expected to be recognized over a remaining average vesting period of 2.0 years.
The Company’s stock-based compensation expense was recognized in operating expenses as follows:
Three Months Ended
(in thousands)March 31, 2026March 31, 2025
Research and development$307 $401 
General and administrative739 883 
Total$1,046 $1,284 
Three Months Ended
(in thousands)March 31, 2026March 31, 2025
Stock options and RSUs$1,036 $1,263 
Employee Stock Purchase Plan10 21 
Total$1,046 $1,284 
The fair value of options granted during the three months ended March 31, 2026 and 2025 was estimated utilizing the following assumptions:
Three Months Ended
March 31, 2026March 31, 2025
Weighted
Average
Weighted
Average
Volatility99.57 %86.51 %
Expected term in years5.985.45
Dividend rate— %— %
Risk-free interest rate3.71 %3.94 %
Fair value of option on grant date$1.32 $0.41 
The following table summarizes the number of options outstanding and the weighted average exercise price:
 Number of Shares Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Life in Years
Aggregate
Intrinsic
Value
(in thousands)
Options outstanding December 31, 202517,613,352 $2.68 6.56$5,332 
Vested and exercisable at December 31, 202511,042,865 3.49 5.25$
Granted4,575,750 1.65 
Exercised(123,024)1.51 
Forfeited or expired(1,204,929)4.20 
Options outstanding March 31, 202620,861,149 2.42 7.38$11,377 
Vested and exercisable at March 31, 202611,724,462 $3.13 5.92$3,552 
At March 31, 2026, there was $13.5 million of unrecognized stock–based compensation expense related to stock option grants, which is expected to be recognized over a remaining average vesting period of 2.87 years.
v3.26.1
INCOME TAXES
3 Months Ended
Mar. 31, 2026
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The Company’s interim income tax provision consists of U.S. federal and state income taxes based on the estimated annual effective tax rate that the Company expects for the full year together with the tax effect of discrete items. Each quarter the Company updates its estimate of the annual effective tax rate and records cumulative adjustments as necessary. As of March 31, 2026, the Company was in a pre-tax loss position and is anticipated to remain so throughout the year. For the three months ended March 31, 2026 and 2025, the Company did not record any tax benefit or expense.
In assessing the realizability of deferred tax assets, management evaluates whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible and/or net operating losses can be utilized. Management assesses all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, prior earnings history, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income. Significant weight is given to positive and negative evidence that is objectively verifiable. Based on these factors, including cumulative losses in recent years, the Company continues to maintain a full valuation allowance against its net deferred tax assets as of March 31, 2026.
On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the United States. The OBBBA includes significant changes, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to certain aspects of the international tax framework and the restoration of favorable tax treatment for certain business expense provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The OBBBA did not have a material impact on the Company’s interim condensed consolidated financial statements for the three-month period ended March 31, 2026, and the Company does not expect the OBBBA to have a material impact on the Company’s provision for income taxes or net income (loss) in future periods.
v3.26.1
COMMITMENTS AND CONTINGENCIES
3 Months Ended
Mar. 31, 2026
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
License Agreements
Northwestern University License Agreement
In December 2016, the Company entered into a license agreement (“Northwestern Agreement”) with Northwestern University (“Northwestern”), pursuant to which Northwestern granted the Company an exclusive, worldwide license to patent rights of certain inventions (“Northwestern Patent Rights”) which relate to a specific compound and related methods of use for such compound, along with certain know-how related to the practice of the inventions claimed in the Northwestern Patent Rights. The Company is developing OV329 under this agreement.
Under the Northwestern Agreement, the Company was granted exclusive rights to research, develop, manufacture and commercialize products utilizing the Northwestern Patent Rights for all uses. The Company has agreed that it will not use the Northwestern Patent Rights to develop any products for the treatment of cancer, but Northwestern may not grant rights in the technology to others for use in cancer. The Company also has an option, exercisable during the term of the agreement to an exclusive license under certain intellectual property rights covering novel compounds with the same or similar mechanism of action as the primary compound that is the subject of the license agreement. Northwestern has retained the right, on behalf of itself and other non-profit institutions, to use the Northwestern Patent Rights and practice the inventions claimed therein for educational and research purposes and to publish information about the inventions covered by the Northwestern Patent Rights.
Upon entry into the Northwestern Agreement, the Company paid an upfront non-creditable one-time license issuance fee of $75,000 and is required to pay an annual license maintenance fee of $20,000, which will be creditable against any royalties payable to Northwestern following first commercial sale of licensed products under the agreement. The Company is responsible for all ongoing costs of filing, prosecuting and maintaining the Northwestern Patent Rights, but also has the right to control such activities using its own patent counsel. In consideration for the rights granted to the Company under the Northwestern Agreement, the Company is required to pay to Northwestern up to an aggregate of $5.3 million upon the achievement of certain development and regulatory milestones for the first product covered by the Northwestern Patent Rights, and upon commercialization of any such products, will be required to pay to Northwestern a tiered royalty on net sales of such products by the Company, its affiliates or sublicensees, at percentages in the low to mid-single-digits, subject to standard reductions and offsets. The Company’s royalty obligations continue on a product-by-product and country-by-country basis until the later of the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country and 10 years following the first commercial sale of such product in such country. If the Company sublicenses a Northwestern Patent Right, it will be obligated to pay to Northwestern a specified percentage of sublicense revenue received by the Company, ranging from the high single-digits to the low-teens.
The Northwestern Agreement requires that the Company use commercially reasonable efforts to develop and commercialize at least one product that is covered by the Northwestern Patent Rights.
Unless earlier terminated, the Northwestern Agreement will remain in force until the expiration of the Company’s payment obligations thereunder. The Company has the right to terminate the agreement for any reason upon prior written notice or for an uncured material breach by Northwestern. Northwestern may terminate the agreement for the Company’s uncured material breach or insolvency.
The Company did not incur any licensing expenses under the Northwestern Agreement during the three months ended March 31, 2026 and 2025.
AstraZeneca AB License Agreement
In December 2021, the Company entered into an exclusive license agreement with AstraZeneca AB (“AstraZeneca”), for a library of early-stage small molecules targeting the KCC2 transporter. Upon execution of the agreement, the Company was obligated to pay an upfront cash payment of $5.0 million and issued shares of the Company’s common stock in an amount that equaled $7.3 million based on the volume-weighted average price of shares of the Company’s common stock for the 30 business days immediately preceding the execution date of the transaction.
Pursuant to the AstraZeneca license agreement, the Company agreed to potential milestone payments of up to $203.0 million upon the achievement of certain developmental, regulatory and sales milestones. The first payment of $3.0 million is due upon the successful completion of the first Phase 2 clinical study of a licensed product following a positive biomarker readout in a Phase 1 clinical study.
Gensaic Equity Agreement and Collaboration and Option Agreement
In August 2022, the Company entered into an equity agreement and a collaboration and option agreement with Gensaic (“Gensaic Collaboration Agreement”). Under the terms of the equity agreement, the Company invested a total of
$5.1 million in exchange for convertible preferred stock in Gensaic. The Company also retained rights to invest in future equity financing rounds. Dr. Jeremy Levin, the Company’s Executive Chairman, is currently the Chairman of Gensaic’s board of directors. The Gensaic Collaboration Agreement involves the research and development of Gensaic’s proprietary platform for certain rare central nervous system (“CNS”) disorder targets. Under the Gensaic Collaboration Agreement, Gensaic granted the Company an option to obtain an exclusive license with respect to certain identified lead phage-derived particle (“PDP”) products, which is exercisable at any time prior to the expiration of the option period. Once a product is identified by the Company that demonstrates sufficient efficacy, the Company may exercise its option with respect to the specific research program for that PDP product.
The Company shall reimburse Gensaic for its research costs related to the specific research plan for PDP products identified. The research plan and budget shall be mutually agreed upon by the parties and shall not exceed $3.0 million in any research year. The Company will record these reimbursement payments as research and development costs in the period the research costs are incurred. In May 2023, the Company identified a lead PDP candidate for further research and provided $3.5 million to Gensaic to support the approved research plan and budget. The amount is expensed as the research and development occurs with the remaining amount included in prepaid expenses and other current assets in the condensed consolidated balance sheets. As of March 31, 2026 and December 31, 2025, $1.0 million remained in prepaid expenses and other current assets. No expense was recognized in the three months ended March 31, 2026 and 2025.
If a product is ultimately commercialized under this agreement, the Company shall make tiered royalty payments to Gensaic in the mid-single to low double-digit range based on the net sales of all licensed PDP products during the royalty term. The Company is also responsible for potential tiered milestone payments of up to $452.0 million based upon the achievement of certain sales milestone events and developmental milestone approvals for three or more products. Gensaic also has the option to become a collaborative partner in the development and commercialization of PDP products in exchange for a fee based on a percentage of the costs incurred by the Company through the date Gensaic exercises its option. The Company would no longer be required to pay Gensaic royalty or milestone payments if Gensaic elects to exercise its option. The Company may terminate the Gensaic Collaboration Agreement by providing written notice to Gensaic 90 days in advance of the termination date.
In January 2026, the Company and Gensaic executed an amendment which provided, among other changes to the original agreement, (a) the ability for the Company to apply the remaining prepaid research balance of $1.0 million to a new research project that may or may not be limited to PDP products and (b) provide an option at the end of the research project to enter into exclusive negotiations to enter into a license and development agreement with associated compensation. Any newly negotiated license and development agreement and compensation would supersede the original milestone and royalty schedules. In the three months ended March 31, 2026, no additional research activities had been performed.
As of March 31, 2026, none of the above described contingent payments were considered probable.
Non-Operating Loss
During the quarter ended September 30, 2024, the Company was the victim of a criminal scheme involving a business email compromise at one of its development collaborators, which led to a fraudulent transfer totaling $1.8 million to a third-party impersonating one of the Company’s development collaborators. A loss was recorded in other income (expense) in the condensed consolidated statement of operations. The Company subsequently recovered the funds in full and recorded a gain in other income (expense) in the condensed consolidated statement of operations in the first quarter of 2025.
Contingencies
Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. The Company is not currently involved in any material legal matters arising in the normal course of business.
Under the terms of their respective employment agreements, each of the Company’s named executive officers is eligible to receive severance payments and benefits upon a termination without “cause” or due to “permanent disability,” or upon “resignation for good reason,” contingent upon the executive officer’s delivery to the Company of a satisfactory release of claims, and subject to the executive officer’s compliance with non-competition and non-solicitation restrictive covenants for two years following the termination date.
v3.26.1
COLLABORATION AND LICENSE AGREEMENTS
3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
COLLABORATION AND LICENSE AGREEMENTS COLLABORATION AND LICENSE AGREEMENTS
Takeda Royalty, License and Termination Agreement
In January 2017, the Company entered into a license and collaboration agreement with Takeda under which the Company licensed from Takeda certain exclusive rights to develop and commercialize soticlestat in certain territories.
In March 2021, the Company entered into the RLT Agreement, pursuant to which Takeda secured rights to the Company’s 50% global share in soticlestat, and the Company granted to Takeda an exclusive worldwide license under the Company’s relevant intellectual property rights to develop and commercialize the investigational medicine soticlestat for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome.
Under the RLT Agreement, all rights in soticlestat are owned by Takeda or exclusively licensed to Takeda by the Company. Takeda assumed all responsibility for, and costs of, both development and commercialization of soticlestat, and the Company no longer had any financial obligation to Takeda under the original collaboration agreement. In March 2021, upon the closing of the RLT Agreement, the Company received a nonrefundable upfront payment of $196.0 million and, is eligible to receive up to an additional $660.0 million upon Takeda achieving developmental, regulatory and sales milestones. Additionally, the Company is entitled to receive tiered royalties beginning in the low double-digits, and up to 20% on sales if regulatory approval was achieved. In October 2023, the Company sold a 13% stake in the royalty, regulatory and commercial milestone payments that the Company is eligible to receive under the RLT Agreement to Ligand Pharmaceuticals, Inc. for $30.0 million.
During the three months ended March 31, 2026 and 2025, no income or expense was recognized pursuant to the RLT Agreement. In June 2024, Takeda issued a press release indicating the soticlestat trials missed their primary endpoints and noted that while Takeda would discuss the program with FDA, Takeda had fully impaired the asset representing soticlestat. In January 2025, Takeda announced the discontinuation of the program.
Marinus Pharmaceuticals Out-License Agreement
In March 2022, the Company entered into an exclusive patent license agreement with Marinus (“Marinus License Agreement”). Under the Marinus License Agreement, the Company granted Marinus an exclusive, non-transferable (except as expressly provided therein), royalty-bearing right and license under certain Ovid patents relating to ganaxolone to develop, make, have made, commercialize, promote, distribute, sell, offer for sale and import licensed products in the territory (which consists of the United States, the European Economic Area, United Kingdom and Switzerland) for the treatment of CDKL5 deficiency disorders. Following the date of regulatory approval by the FDA of the first licensed product in the territory, which was received in March 2022, Marinus issued, at the Company’s option, 123,255 shares of Marinus common stock, par value $0.001 per share, as payment. The Marinus License Agreement also provides for payment of royalties from Marinus to the Company in single-digits on net sales of each such licensed product sold.
In February 2025, Immedica closed a cash purchase of Marinus, resulting in the sale of the Company’s equity position in Marinus for $70,000.
In June 2025, the Company entered into an amendment to the Marinus License Agreement with Immedica wherein the parties agreed to replace ongoing royalty payment obligations and add additional licensing for a one-time payment of $7.0 million, which was remitted to the Company pursuant to the agreement and recognized as revenue in 2025. Of the $7.0 million, $6.3 million was related to the royalties and existing licenses and $0.7 million was related to a six-month option for Marinus to include additional patent assignments or expansion of the territory or field of use. The Company initially recorded the value of the option as deferred revenue and upon the December 2025, expiration of the option period, recorded the remaining deferred revenue as revenue.
Graviton License Agreement and Equity Purchase
In April 2023, the Company entered into a collaboration and license agreement with Graviton (“Graviton Agreement”), whereby it secured from Graviton an exclusive license to develop and commercialize Graviton’s library of ROCK2 inhibitors including their lead program GV101 (OV888) in rare CNS disorders (excluding amyotrophic lateral sclerosis) worldwide (excluding China, Hong Kong, Macau and Taiwan). Under the Graviton Agreement, the Company and Graviton plan to investigate GV101 (OV888) in cerebral cavernous malformations as well as Graviton’s library of ROCK2 inhibitors in other rare CNS disorders. The Company will be responsible for all development and commercialization costs of the products. Should the Company receive regulatory approval and commercialize any of Graviton’s ROCK2 inhibitors, it will pay Graviton tiered royalties on net sales ranging from the mid- to high-teens. As part of the Graviton Agreement, the Company also purchased shares of Graviton’s preferred stock for $10.0 million. The Company recorded the purchase of the preferred stock as a long-term equity investment on its condensed consolidated balance sheets. In December 2023, March 2024 and December 2025, the Company recognized unrealized gains on the
investment due to an observable change in price and recorded the gain in other income (expense), net in the condensed consolidated statements of operations. The program related to this collaboration agreement is currently paused.
v3.26.1
RELATED PARTY TRANSACTIONS
3 Months Ended
Mar. 31, 2026
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS
In March 2021, the Company entered into the RLT Agreement with Takeda. For a description of the RLT Agreement, see Note 11.
In the 2025 Private Placement, Dr. Levin, the Company Executive Chairman, purchased 71 shares of Series B Preferred Stock, 47,333 Series A Warrants, and 35,500 Series B Warrants for an aggregate purchase price of approximately $99,000. On March 24, 2026, Dr. Levin exercised Series A Warrants to purchase 47,773 shares of common stock for a purchase price of $66,266. For additional information on the 2025 Private Placement, see Note 7.
v3.26.1
NET LOSS PER SHARE
3 Months Ended
Mar. 31, 2026
Earnings Per Share [Abstract]  
NET LOSS PER SHARE NET LOSS PER SHARE
The basic and diluted net loss per common share is presented in conformity with the two-class method required for participating securities and multiple classes of shares. The Company considers its preferred stock to be in-substance common stock (see Note 2) and reflects it as a class of common stock for purposes of calculating net loss per share. While there were no shares of Series A Preferred Stock outstanding at March 31, 2026 and December 31, 2025, the conversion of the Series A Preferred Stock occurred in December 2025 and the weighted average shares outstanding for previous applicable periods are used in calculating net loss per share. The Series B Preferred Stock and the Warrants are participating securities.
Diluted net loss per common share is equivalent to the basic net loss per common share due to the exclusion of outstanding stock options, convertible preferred stock not considered in-substance common stock, outstanding common warrants (excluding Pre-Funded Warrants) and unvested RSUs because the inclusion of these securities would result in an anti-dilutive effect on per common share amounts.
The following table summarizes the calculation of basic and diluted net loss per share:
For the Three Months Ended March 31, 2026For the Three Months Ended March 31, 2025
(in thousands, except share and per share data)Series A Preferred StockCommon StockSeries A Preferred StockCommon Stock
Net loss per share, basic and diluted:
Allocation of net loss
$— $(16,988)$(177)$(10,058)
Weighted average shares outstanding, basic and diluted
— 136,171,393 1,250 71,045,265 
Net loss per share, basic and diluted
$— $(0.12)$(141.57)$(0.14)
The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:
For the Period Ended
March 31, 2026December 31, 2025
Stock options to purchase common stock20,861,149 17,613,352 
Common stock issuable upon exercise of Series A Warrants19,483,996 38,481,325 
Common stock issuable upon exercise of Series B Warrants28,861,000 28,861,000 
Unvested RSUs669,545 420,080 
50,066,694 85,375,757 
v3.26.1
SEGMENT REPORTING
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
The Company has determined that it operates as one segment focused on developing medicines for brain disorders with significant unmet need. The Company’s precommercial drug development candidates have similar economic and other characteristics, including all being in the small molecule therapeutic class which shares target markets, development pathways and regulatory environments. The CODM is the President and CEO, who reviews profit and loss information on
a consolidated basis to assess performance and make operating and planning decisions, including resource allocations among active programs. The determination of the single segment is consistent with the information provided to the CODM. As the Company’s operations are comprised of a single reporting segment, the segment assets are reflected on the accompanying condensed consolidated balance sheet as “total assets.” Segment asset information is not used by the CODM to make operating and planning decisions or allocate resources.
The following tables summarize the Company’s segment information as presented to the CODM for the periods indicated:
For the Three Months Ended March 31,
(in thousands)20262025
Revenue$— $130 
Payroll and payroll-related expenses1,924 1,837 
Direct program expenses
OV3295,463 859 
KCC2 library1,914 2,778 
OV4071982 — 
OV888 (GV101)— 339 
Other programs424 268 
Total direct program expenses8,785 4,244 
Other research and development expenses472 578 
Total research and development expenses11,181 6,659 
Payroll and payroll-related expenses2,115 3,130 
Legal and professional fees2,771 1,451 
General office expenses1,779 1,440 
Total general and administrative expenses6,665 6,021 
Total operating expenses17,846 12,680 
Operating loss(17,846)(12,550)
Other income (expense), net858 2,315 
Net loss
$(16,988)$(10,235)
Other research and development expenses include general office expenses allocated to research and development, including costs related to rent, depreciation of leasehold improvements and nonclinical contract labor. Other income (expense), net includes a gain from fraudulent funds transfer recovery and interest/accretion income on securities.
Other significant segment information includes:
For the Three Months Ended March 31,
(in thousands)20262025
Stock-based compensation expense1,046 1,284 
Interest/accretion income on securities737 491 
Severance expense— 435 
Gain from recovery of fraudulent funds transfer— 1,800 
Depreciation and amortization35 141 
v3.26.1
Insider Trading Arrangements
3 Months Ended
Mar. 31, 2026
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended
Mar. 31, 2026
Accounting Policies [Abstract]  
Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Financial Statements
The interim condensed consolidated balance sheet at March 31, 2026 and the condensed consolidated statements of operations, comprehensive loss, cash flows, and stockholders’ equity for the three months ended March 31, 2026 and 2025 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and follow the requirements of the SEC for interim reporting. As permitted under those rules, certain notes or other financial information that are normally required by GAAP are condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual financial
statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three months ended March 31, 2026 and 2025 are not necessarily indicative of the results to be expected for the year ending December 31, 2026 or for any other future annual or interim period. The balance sheet as of December 31, 2025 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements as of and for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K.
Basis of Presentation and Consolidation Basis of Presentation and Consolidation
The accompanying interim condensed consolidated financial statements have been prepared in conformity with GAAP and include the accounts of Ovid Therapeutics Inc. and its wholly owned subsidiaries, Ovid Therapeutics Australia Pty Ltd and Ovid Therapeutics Hong Kong Ltd. All intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.
Marketable Securities Marketable Securities
Marketable securities consist of investments in U.S. treasury instruments which are considered available-for-sale securities. The Company classifies its marketable securities with original maturities of less than three months as cash equivalents on its condensed consolidated balance sheets. The Company classifies its marketable securities with maturities of less than one year from the balance sheet date as current assets on its condensed consolidated balance sheets. The Company classifies its marketable securities with maturities of greater than twelve months as noncurrent assets on its consolidated balance sheets. Unrealized gains and losses on these securities that are determined to be temporary are reported as a separate component of accumulated other comprehensive (loss) income in stockholders’ equity.
Restricted Cash Restricted Cash
The Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as noncurrent unless restrictions are expected to be released in the next 12 months.
Long-Term Equity Investments Long-Term Equity Investments
Long-term equity investments consist of equity investments in the preferred shares of Gensaic, Inc., formerly M13 Therapeutics, Inc. (“Gensaic”), and Graviton Bioscience Corporation (“Graviton”), both privately held corporations. The preferred shares are not considered in-substance common stock, and the investments are accounted for at cost, with adjustments for observable changes in prices or impairments, and are classified within long-term equity investments on the condensed consolidated balance sheets with adjustments recognized in other income (expense), net on the condensed consolidated statements of operations. The Company has determined that these equity investments do not have a readily determinable fair value and elected the measurement alternative. Therefore, the carrying amount of the equity investments will be adjusted to fair value at the time of the next observable price change for the identical or similar investment of the same issuer or when an impairment is recognized. Each reporting period, the Company performs a qualitative assessment to evaluate whether the investments are impaired. The assessment includes a review of recent operating results and trends, recent sales/acquisitions of the investees’ securities, and other publicly available data. If an investment is determined to be impaired, the Company will then write it down to its estimated fair value. As of March 31, 2026 and December 31, 2025, the equity investment in Gensaic had a carrying value of $5.1 million. As of March 31, 2026 and December 31, 2025, the equity investment in Graviton had a carrying value of $36.8 million. The initial investment in Graviton was $10.0 million, and cumulative measurement adjustments based on observable price increases totaling $26.8 million have been recognized, recorded in other income (expense), net within the statement of operations.
No impairments were recognized in the three month periods ended March 31, 2026 and 2025.
Fair Value of Financial Instruments Fair Value of Financial Instruments
Financial Accounting Standards Board (“FASB”) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest
priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).
The three levels of the fair value hierarchy are as follows:
Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company’s Level 1 assets consisted of investments in a U.S. treasury money market fund of $81.2 million as of March 31, 2026, and U.S. treasury money market funds totaling $25.8 million as of December 31, 2025.
Level 2—Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company’s Level 2 assets consisted of U.S. treasury bills, totaling $71.5 million as of March 31, 2026 and $26.8 million as of December 31, 2025.
Level 3—Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. There were no Level 3 assets as of March 31, 2026 or December 31, 2025. The Company’s Level 3 liabilities consist of a royalty monetization liability that is immaterial as of March 31, 2026 and December 31, 2025 due to the improbability that the program would be further developed into a commercial product.
The carrying amounts reported in the balance sheets for cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair values based on the short-term maturity of these instruments.
Leases Leases
The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with FASB Accounting Standards Codification (“ASC”) 842. Operating leases are included in right-of-use (“ROU”) assets, current liabilities, and long-term lease liability in the Company’s condensed consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.
Property and Equipment Property and Equipment
Property and equipment are stated at cost and depreciated over their estimated useful lives of three years using the straight-line method. Repair and maintenance costs are expensed. The Company reviews the recoverability of all long-lived assets, including the related useful life, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable.
Royalty Monetization Liability Royalty Monetization Liability
The Company accounted for its sale to Ligand Pharmaceuticals Incorporated (“Ligand”) of a 13% share of royalties and milestones owed to the Company related to the potential approval and commercialization of soticlestat (“Ligand Agreement”) in accordance with ASC 470, Debt, classifying the proceeds received from the sale to Ligand as debt as the Company determined that it had significant continuing involvement in the generation of the cash flows to Ligand. The Company further elected to account for the debt at fair value with changes in the fair value of the debt classified as other income (expense) in the consolidated statements of operations. In June 2024, Takeda issued a press release indicating the soticlestat trials missed their primary endpoints and noted that while Takeda would discuss the program with the FDA, Takeda fully impaired the asset representing soticlestat. In January 2025, Takeda announced the discontinuation of the program.
Research and Development Expenses Research and Development Expenses
The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as contracted services, license fees, and other external costs. Research and development expenses also include the cost of licensing agreements acquired from third parties.
Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received in accordance with ASC 730, Research and Development.
Stock-Based Compensation Stock-Based Compensation
The Company accounts for its stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation, which establishes accounting for stock-based awards granted for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company estimates the fair value of all option awards granted using the Black-Scholes valuation model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk-free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require judgment and any changes could have an impact in the determination of stock-based compensation expense. The Company elected an accounting policy to record forfeitures as they occur. The Company recognizes stock-based compensation expense based on the fair value of the award on the date of the grant. The compensation expense is recognized over the vesting period under the straight-line method. The Company aggregates employee and nonemployee awards for certain disclosures since nonemployee awards are not material.
Income Taxes Income Taxes
The Company accounts for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as for net operating loss carryforwards and research and development credits. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The impact of a change in the tax laws is recorded in the period in which the law is enacted.
Net Loss per Share Net Loss per Share
The rights and preferences of the non-voting Series A convertible preferred stock (“Series A Preferred Stock”) are negligible relative to common stock, therefore the Series A Preferred Stock is treated as in-substance common stock on an as-converted basis when allocating net loss to actual and in-substance shares of common stock. The Company applies the two-class method to allocate earnings between common stock, Series A Preferred Stock, and other securities deemed in-substance common stock and participating securities, if any. Pre-funded warrants to purchase shares of common stock (the “Pre-Funded Warrants”) are included in the number of weighted-average shares of common stock outstanding for net loss per share calculations.
Net loss per share of common stock is determined by dividing net loss attributable to common stockholders by the basic weighted-average shares of common stock outstanding during the period. Net loss per diluted share attributable to common stockholders adjusts the basic earnings per share attributable to common stockholders and the weighted-average number of shares of common stock outstanding for the potential dilutive impact of stock options, warrants, and restricted stock units (“RSUs”) using the treasury-stock method and the potential impact of any preferred stock using the if-converted method. Net loss per diluted share attributable to common stockholders omits the inclusion of stock options, common stock issuable upon conversion of Series A Preferred Stock, warrants (except the Pre-Funded Warrants) and unvested RSUs, as these securities would be anti-dilutive.
Retirement Plan Retirement Plan
The Company maintains a 401(k) retirement plan for its employees that is intended to qualify under Sections 401(a) and 501(a) of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). The Company provides all active employees with a 100% matching contribution equal to 3% of an employee’s eligible deferred compensation and a 50% matching contribution on employee contributions that are between 3% and 5% of an employee’s eligible deferred compensation. These safe harbor contributions vest immediately. For the three months ended March 31, 2026 and 2025, the Company contributed $66,000 and $74,000, respectively.
Revenue Recognition Revenue Recognition
Under ASC 606, Revenue from Contracts with Customers, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services the
Company transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.
Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.
If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.
Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered. The Company defers recognition of upfront license fees until the performance obligations are satisfied.
Segment Reporting Segment Reporting
Under Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): “Improvements to Reportable Segment Disclosures” (“ASU 2023-07”), the Company discloses significant segment expenses regularly provided to the chief operating decision maker (“CODM”) and discloses the title and position of the CODM.
Common and Pre-Funded Warrants Common and Pre-Funded Warrants
The Company has issued freestanding warrants to purchase shares of its common stock in connection with financing activities and accounts for them in accordance with applicable accounting guidance as either liabilities or as equity instruments depending on the specific terms of the underlying warrant agreements. The Company has issued Pre-Funded Warrants in connection with financing activities and common warrant exercises and accounts for them as equity instruments in accordance with applicable accounting guidance.
Recent Accounting Pronouncements Recent Accounting Pronouncements
The Company has reviewed recently issued accounting standards and plans to adopt those that are applicable. The Company does not expect the adoption of those standards to have a material impact on its financial position, results of operations or cash flows.
In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, (“ASU 2023-09”), which is effective for annual periods beginning after December 15, 2024. ASU 2023-09 intends to enhance the transparency as well as usefulness of income tax disclosures, primarily related to the rate reconciliation and income taxes paid. The Company has implemented ASU 2023-09 retrospectively for years ended December 2024 and 2025, as reported in the Company’s Annual Report on Form 10-K for the period ending December 31, 2025.
In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires the disaggregation of certain expense captions into specified categories in disclosures within the notes to the consolidated financial statements to provide enhanced transparency into the expense captions presented on the face of the statements of income and comprehensive income. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, with early adoption permitted, and may be applied either prospectively or retrospectively to financial statements issued for reporting periods after the effective date of ASU 2024-03 or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its related disclosures.
The Company adopts new pronouncements relating to GAAP applicable to the Company as they are issued, and based upon the effective dates included in the pronouncements. Management does not believe that any recently issued, but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements.
v3.26.1
CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables)
3 Months Ended
Mar. 31, 2026
Cash and Cash Equivalents [Abstract]  
Schedule of Debt Securities, Available-for-Sale
The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of March 31, 2026 and December 31, 2025:
March 31, 2026
(in thousands)Amortized CostGross Unrealized Holding GainsGross Unrealized Holding LossesFair Value
Cash$12,885 $— $— $12,885 
Cash equivalents81,178 — — 81,178 
Marketable securities71,651 — (116)71,535 
Total cash, cash equivalents and marketable securities$165,714 $— $(116)$165,598 
December 31, 2025
(in thousands)Amortized CostGross Unrealized Holding GainsGross Unrealized Holding LossesFair Value
Cash$516 $— $— $516 
Cash equivalents12,636 — 12,637 
Marketable securities77,315 — (21)77,294 
Total cash, cash equivalents and marketable securities$90,467 $$(21)$90,447 
Schedule of Cash and Cash Equivalents
The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of March 31, 2026 and December 31, 2025:
March 31, 2026
(in thousands)Amortized CostGross Unrealized Holding GainsGross Unrealized Holding LossesFair Value
Cash$12,885 $— $— $12,885 
Cash equivalents81,178 — — 81,178 
Marketable securities71,651 — (116)71,535 
Total cash, cash equivalents and marketable securities$165,714 $— $(116)$165,598 
December 31, 2025
(in thousands)Amortized CostGross Unrealized Holding GainsGross Unrealized Holding LossesFair Value
Cash$516 $— $— $516 
Cash equivalents12,636 — 12,637 
Marketable securities77,315 — (21)77,294 
Total cash, cash equivalents and marketable securities$90,467 $$(21)$90,447 
v3.26.1
PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Tables)
3 Months Ended
Mar. 31, 2026
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Property and equipment is summarized as follows:
(in thousands)March 31,
2026
December 31,
2025
Furniture and equipment$1,534 $1,534 
Leasehold improvements306 306 
Less accumulated depreciation(1,623)(1,588)
Total property and equipment, net$217 $252 
v3.26.1
LEASES (Tables)
3 Months Ended
Mar. 31, 2026
Leases [Abstract]  
Schedule of ROU Asset and Lease Liabilities Related to Operating Lease
ROU asset and lease liabilities related to the Company’s operating lease are as follows:
(in thousands)March 31,
2026
December 31,
2025
ROU asset, net$11,298 $11,610 
Current lease liability1,459 1,433 
Long-term lease liability11,611 11,986 
Schedule of Operating Lease Cost
The components of operating lease cost for the three months ended March 31, 2026 were as follows:
(in thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Operating lease cost$542 $542 
Variable lease cost— — 
Schedule of Future Minimum Commitments
Future minimum commitments under the non-cancelable operating lease are as follows:
(in thousands)
2026$1,737 
20272,316 
20282,469 
20292,469 
20302,469 
Thereafter4,939 
$16,399 
v3.26.1
ACCRUED EXPENSES (Tables)
3 Months Ended
Mar. 31, 2026
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses
Accrued expenses consist of the following:
(in thousands)March 31,
2026
December 31,
2025
Banking and placement fees$1,916 $— 
Payroll and bonus accrual822 3,106 
Research and development accrual1,537 1,191 
Professional fees accrual703 350 
Accrued taxes169 142 
Other266 110 
Total$5,413 $4,899 
v3.26.1
STOCKHOLDERS’ EQUITY (Tables)
3 Months Ended
Mar. 31, 2026
Equity [Abstract]  
Warrants And Rights, Fair Value Measurement Assumptions
The following table presents the level 3 inputs used in the valuation models:
Series A WarrantsSeries B
Warrants
6-month expiry5-year expiry
Probability97.5 %2.5 %
Stock price$1.79 $1.79 $1.79 
Strike price$1.40 $1.40 $1.40 
Expected volatility115 %115 %115 %
Expected term in years0.55.0
Dividend rate— — — 
Risk-free interest rate3.81 %3.75 %3.75 %
Fair value$0.73 $1.51 $1.29 
Schedule of Stockholders' Equity Note, Warrants or Rights
The following table summarizes the number of Warrants and Pre-Funded Warrants outstanding as of March 31, 2026, the weighted average exercise price, and the aggregate intrinsic value:
Series A and Series B Warrants
Pre-Funded Warrants
Weighted Average Exercise PriceAggregate Intrinsic Value
(in thousands)
Outstanding, December 31, 2025
67,342,325 $1.40 $55,221 
Pre-Funded Warrants purchased in 2026 Private Placement
— 10,701,710 0.001 23,747 
Series A Warrants exercised into common stock
(16,140,663)— — — 
Series A Warrants exercised into Pre-Funded Warrants(2,856,666)2,856,666 0.001 6,339 
Outstanding, March 31, 2026
48,344,996 13,558,376 $1.09 $68,067 
v3.26.1
STOCK-BASED COMPENSATION (Tables)
3 Months Ended
Mar. 31, 2026
Share-Based Payment Arrangement [Abstract]  
Schedule of Recognized Stock-based Compensation Expense
The Company’s stock-based compensation expense was recognized in operating expenses as follows:
Three Months Ended
(in thousands)March 31, 2026March 31, 2025
Research and development$307 $401 
General and administrative739 883 
Total$1,046 $1,284 
Schedule of Allocation of Stock-based Compensation Expense by Plan
Three Months Ended
(in thousands)March 31, 2026March 31, 2025
Stock options and RSUs$1,036 $1,263 
Employee Stock Purchase Plan10 21 
Total$1,046 $1,284 
Schedule of Assumptions Used to Compute Fair Value of Employee Option Granted
The fair value of options granted during the three months ended March 31, 2026 and 2025 was estimated utilizing the following assumptions:
Three Months Ended
March 31, 2026March 31, 2025
Weighted
Average
Weighted
Average
Volatility99.57 %86.51 %
Expected term in years5.985.45
Dividend rate— %— %
Risk-free interest rate3.71 %3.94 %
Fair value of option on grant date$1.32 $0.41 
Schedule of Options Outstanding and Weighted Average Exercise Price
The following table summarizes the number of options outstanding and the weighted average exercise price:
 Number of Shares Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Life in Years
Aggregate
Intrinsic
Value
(in thousands)
Options outstanding December 31, 202517,613,352 $2.68 6.56$5,332 
Vested and exercisable at December 31, 202511,042,865 3.49 5.25$
Granted4,575,750 1.65 
Exercised(123,024)1.51 
Forfeited or expired(1,204,929)4.20 
Options outstanding March 31, 202620,861,149 2.42 7.38$11,377 
Vested and exercisable at March 31, 202611,724,462 $3.13 5.92$3,552 
v3.26.1
NET LOSS PER SHARE (Tables)
3 Months Ended
Mar. 31, 2026
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Earnings Loss Per Share
The following table summarizes the calculation of basic and diluted net loss per share:
For the Three Months Ended March 31, 2026For the Three Months Ended March 31, 2025
(in thousands, except share and per share data)Series A Preferred StockCommon StockSeries A Preferred StockCommon Stock
Net loss per share, basic and diluted:
Allocation of net loss
$— $(16,988)$(177)$(10,058)
Weighted average shares outstanding, basic and diluted
— 136,171,393 1,250 71,045,265 
Net loss per share, basic and diluted
$— $(0.12)$(141.57)$(0.14)
Schedule of Computations of Diluted Weighted-Average Shares Outstanding
The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:
For the Period Ended
March 31, 2026December 31, 2025
Stock options to purchase common stock20,861,149 17,613,352 
Common stock issuable upon exercise of Series A Warrants19,483,996 38,481,325 
Common stock issuable upon exercise of Series B Warrants28,861,000 28,861,000 
Unvested RSUs669,545 420,080 
50,066,694 85,375,757 
v3.26.1
SEGMENT REPORTING (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Direct Expenses With Respect to Program Segments
The following tables summarize the Company’s segment information as presented to the CODM for the periods indicated:
For the Three Months Ended March 31,
(in thousands)20262025
Revenue$— $130 
Payroll and payroll-related expenses1,924 1,837 
Direct program expenses
OV3295,463 859 
KCC2 library1,914 2,778 
OV4071982 — 
OV888 (GV101)— 339 
Other programs424 268 
Total direct program expenses8,785 4,244 
Other research and development expenses472 578 
Total research and development expenses11,181 6,659 
Payroll and payroll-related expenses2,115 3,130 
Legal and professional fees2,771 1,451 
General office expenses1,779 1,440 
Total general and administrative expenses6,665 6,021 
Total operating expenses17,846 12,680 
Operating loss(17,846)(12,550)
Other income (expense), net858 2,315 
Net loss
$(16,988)$(10,235)
Schedule of Other Operating Cost and Expense, by Component
Other significant segment information includes:
For the Three Months Ended March 31,
(in thousands)20262025
Stock-based compensation expense1,046 1,284 
Interest/accretion income on securities737 491 
Severance expense— 435 
Gain from recovery of fraudulent funds transfer— 1,800 
Depreciation and amortization35 141 
v3.26.1
NATURE OF OPERATIONS (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Cash, cash equivalents, and marketable securities $ 165,598   $ 90,447
Accumulated deficit (338,701)   $ (321,713)
Working capital 144,400    
Cash outflows from operating activities (13,899) $ (10,280)  
Net loss $ (16,988) $ (10,235)  
v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Summary of Significant Accounting Policy [Line Items]      
Long-term equity investments $ 41,961,000   $ 41,961,000
Impairment recognized on equity investments 0 $ 0  
Debt securities, available-for-sale $ 71,535,000   77,294,000
Estimated useful life (in years) 3 years    
Contribution amount to retirement plan $ 66,000 $ 74,000  
Pension Plan, Matching Scenario One      
Summary of Significant Accounting Policy [Line Items]      
Percentage of company matching contribution to 401(k) retirement plan 100.00%    
Percentage of eligible employees' contribution 3.00%    
Pension Plan, Matching Scenario Two      
Summary of Significant Accounting Policy [Line Items]      
Percentage of company matching contribution to 401(k) retirement plan 50.00%    
Pension Plan, Matching Scenario Two | Minimum      
Summary of Significant Accounting Policy [Line Items]      
Percentage of eligible employees' contribution 3.00%    
Pension Plan, Matching Scenario Two | Maximum      
Summary of Significant Accounting Policy [Line Items]      
Percentage of eligible employees' contribution 5.00%    
Level 2      
Summary of Significant Accounting Policy [Line Items]      
Debt securities, available-for-sale $ 71,500,000   26,800,000
Level 3      
Summary of Significant Accounting Policy [Line Items]      
Debt securities, available-for-sale 0   0
Money Market Funds and Short-term Investments | Level 1      
Summary of Significant Accounting Policy [Line Items]      
Fair value assets 81,200,000   25,800,000
Gensaic, Inc      
Summary of Significant Accounting Policy [Line Items]      
Long-term equity investments 5,100,000   5,100,000
Graviton Bioscience Corporation      
Summary of Significant Accounting Policy [Line Items]      
Long-term equity investments 36,800,000   $ 36,800,000
Purchase of long term investment 10,000,000.0    
Equity securities without readily determinable fair value, upward price adjustment, cumulative amount $ 26,800,000    
Ligand Pharmaceuticals Incorporated | Purchase Agreement      
Summary of Significant Accounting Policy [Line Items]      
Royalty monetization liability, percentage share of royalties and milestones 13.00%    
v3.26.1
CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES - Schedule of Fair Value of Cash and Cash Equivalents and Gross Unrealized Holding Gains and Losses (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Cash and Cash Equivalents [Abstract]    
Cash Amortized cost $ 12,885 $ 516
Cash equivalents, Amortized Cost 81,178 12,636
Cash equivalents, Gross Unrealized Holding Gains 0 1
Cash equivalents, Gross Unrealized Holding Losses 0 0
Cash equivalents, Fair Value 81,178 12,637
Marketable securities, Amortized cost 71,651 77,315
Gross Unrealized Holding Gains 0 0
Gross Unrealized Holding Losses (116) (21)
Debt securities, available-for-sale 71,535 77,294
Total cash, cash equivalents and marketable securities, Amortized Cost 165,714 90,467
Total cash, cash equivalents and marketable securities, Gross Unrealized Holding Gains 0 1
Total cash, cash equivalents and marketable securities, Gross Unrealized Holding Losses (116) (21)
Total cash, cash equivalents and marketable securities, Fair Value $ 165,598 $ 90,447
v3.26.1
CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Details)
3 Months Ended
Mar. 31, 2026
USD ($)
Investment
Mar. 31, 2025
USD ($)
Dec. 31, 2025
Investment
Cash and Cash Equivalents [Abstract]      
Number of securities in an unrealized loss position for more than 12 months | Investment 0   0
Gains or losses on available-for-sale securities | $ $ 0 $ 0  
v3.26.1
PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Property, Plant and Equipment [Line Items]    
Less accumulated depreciation $ (1,623) $ (1,588)
Property and equipment, net 217 252
Furniture and equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 1,534 1,534
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 306 $ 306
v3.26.1
PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS - Additional Information (Details) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Property, Plant and Equipment [Abstract]      
Depreciation expense $ 35,000 $ 87,000  
Intangible assets, net of accumulated amortization 0   $ 38,000
Amortization expense $ 0 $ 53,000  
v3.26.1
LEASES - Additional Information (Details)
ft² in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2026
USD ($)
Dec. 31, 2025
USD ($)
Mar. 10, 2022
ft²
Short-Term Debt [Line Items]      
Operating lease, term of contract (in years)     10 years
Land subject to ground leases (sqft) | ft²     19
Rent lease $ 2,300    
Restricted cash $ 1,931 $ 1,931  
Remaining lease terms (in years) 6 years    
Renewal option term (in years) 5 years    
Lease incremental borrowing rate (as percent) 7.02%    
Letter of Credit      
Short-Term Debt [Line Items]      
Restricted cash $ 1,900    
v3.26.1
LEASES - Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Leases [Abstract]    
ROU asset, net $ 11,298 $ 11,610
Current lease liability 1,459 1,433
Long-term lease liability $ 11,611 $ 11,986
v3.26.1
LEASES - Schedule of Components of Operating Lease Cost (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Leases [Abstract]    
Operating lease cost $ 542 $ 542
Variable lease cost $ 0 $ 0
v3.26.1
LEASES - Schedule of Future Minimum Commitments Under the Non-Cancelable Operating Lease (Details)
$ in Thousands
Mar. 31, 2026
USD ($)
Leases [Abstract]  
2026 $ 1,737
2027 2,316
2028 2,469
2029 2,469
2030 2,469
Thereafter 4,939
Total operating lease $ 16,399
v3.26.1
ACCRUED EXPENSES (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Payables and Accruals [Abstract]    
Banking and placement fees $ 1,916 $ 0
Payroll and bonus accrual 822 3,106
Research and development accrual 1,537 1,191
Professional fees accrual 703 350
Accrued taxes 169 142
Other 266 110
Total $ 5,413 $ 4,899
v3.26.1
STOCKHOLDERS’ EQUITY - Narrative (Details)
1 Months Ended 3 Months Ended
Apr. 17, 2026
USD ($)
shares
Mar. 19, 2026
USD ($)
$ / shares
shares
Dec. 31, 2025
$ / shares
shares
Oct. 31, 2025
USD ($)
$ / shares
shares
Nov. 30, 2023
USD ($)
Mar. 31, 2026
USD ($)
vote
$ / shares
shares
Mar. 31, 2025
USD ($)
Class of Stock [Line Items]              
Common stock, shares authorized (in shares)     315,000,000     315,000,000  
Preferred stock, shares authorized (in shares)           10,000,000  
Number of votes per share | vote           1  
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares     $ 1.40     $ 1.09  
Proceeds from exercise of Series A warrants into shares of common stock and pre-funded warrants | $           $ 26,593,000 $ 0
Dividends declared | $           0  
Common stock issuable upon exercise of Series B Warrants              
Class of Stock [Line Items]              
Warrants value per share (in dollars per share) | $           $ 1.29  
Pre-Funded Warrants              
Class of Stock [Line Items]              
Class of warrant outstanding           13,558,376  
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares           $ 0.001  
2025 Private Placement              
Class of Stock [Line Items]              
Sale of stock, price per share (in dollars per share) | $ / shares       $ 1,400      
Initial net proceeds | $       $ 75,100,000      
Payments of stock issuance costs | $       5,700,000      
Potential proceeds from warrant exercises | $       $ 40,000,000.0      
2025 Private Placement | Common stock issuable upon exercise of Series B Warrants              
Class of Stock [Line Items]              
Class of warrant or right (in shares)       1,000      
2025 Private Placement | Series A Warrants              
Class of Stock [Line Items]              
Proceeds from exercise of Series A warrants into shares of common stock and pre-funded warrants | $           $ 26,600,000  
Warrants to purchase shares, number received (in shares)           18,997,329  
Warrants exercised           16,140,663  
2025 Private Placement | Series A Warrants | Subsequent Event              
Class of Stock [Line Items]              
Proceeds from exercise of Series A warrants into shares of common stock and pre-funded warrants | $ $ 53,900,000            
Warrants exercised 33,597,860            
2025 Private Placement | Common stock issuable upon exercise of Series B Warrants              
Class of Stock [Line Items]              
Class of warrant outstanding           0  
Warrants exercised           0  
2025 Private Placement | Pre-Funded Warrants              
Class of Stock [Line Items]              
Warrants exercised           2,856,666  
2025 Private Placement | Pre-Funded Warrants | Subsequent Event              
Class of Stock [Line Items]              
Warrants exercised 4,883,464            
March 2026 Private Placement              
Class of Stock [Line Items]              
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares     $ 0.001        
Initial net proceeds | $   $ 56,200,000          
At-The-Market Offering Program              
Class of Stock [Line Items]              
Maximum value of shares authorized in ATM offering program | $         $ 250,000,000.0    
Common stock issuable upon exercise of Series A Warrants              
Class of Stock [Line Items]              
Preferred stock, shares designated (in shares)           10,000  
Preferred stock, shares issued (in shares)           0  
Preferred stock, shares outstanding (in shares)     0     0  
Number of shares of common stock per share of preferred stock (in shares)     1,000        
Common stock issuable upon exercise of Series B Warrants              
Class of Stock [Line Items]              
Preferred stock, shares authorized (in shares)           57,722  
Preferred stock, shares issued (in shares)           0  
Preferred stock, shares outstanding (in shares)           0  
Common stock issuable upon exercise of Series B Warrants | 2025 Private Placement              
Class of Stock [Line Items]              
Sale of stock (in shares)       57,722      
Temporary equity, liquidation preference per share | $ / shares       $ 1,400      
Preferred stock value (in dollars per share) | $ / shares           $ 1.79  
Common stock issuable upon exercise of Series B Warrants | 2025 Private Placement | Chief Executive Officer              
Class of Stock [Line Items]              
Sale of stock (in shares)       71      
Series A Preferred Stock              
Class of Stock [Line Items]              
Conversion of series A common warrants to shares of common stock (in shares)     1,250,000        
Series A Warrants | 2025 Private Placement              
Class of Stock [Line Items]              
Number of securities called by warrants or rights (in shares)       38,481,325      
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares       $ 1.40      
Warrants value per share (in dollars per share) | $           $ 0.75  
Series A Warrants | 2025 Private Placement | Chief Executive Officer              
Class of Stock [Line Items]              
Number of securities called by warrants or rights (in shares)       47,333      
Common stock issuable upon exercise of Series B Warrants | 2025 Private Placement              
Class of Stock [Line Items]              
Number of securities called by warrants or rights (in shares)       500      
Class of warrant or right (in shares)       28,861,000      
Company common stock equal or exceeds (in percent)       3      
Number of trading days       20 days      
Number of consecutive trading days       30 days      
Warrants value per share (in dollars per share) | $           $ 1.29  
Common stock issuable upon exercise of Series B Warrants | 2025 Private Placement | Chief Executive Officer              
Class of Stock [Line Items]              
Number of securities called by warrants or rights (in shares)       35,500      
Series B Preferred Stock and Series A warrants | 2025 Private Placement              
Class of Stock [Line Items]              
Common stock and-or pre-funded warrant issued per security (in shares)       666.66      
Common Stock | March 2026 Private Placement              
Class of Stock [Line Items]              
Sale of stock (in shares)   19,154,321          
Sale of stock, price per share (in dollars per share) | $ / shares   $ 2.01          
Common Stock | At-The-Market Offering Program              
Class of Stock [Line Items]              
Sale of stock (in shares)           1,500,000  
Initial net proceeds | $           $ 2,400,000  
Maximum value of shares authorized in ATM offering program | $         75,000,000.0    
Remaining value available in ATM offering program | $         $ 72,600,000    
Pre-Funded Warrants | March 2026 Private Placement              
Class of Stock [Line Items]              
Sale of stock (in shares)   10,701,710          
Sale of stock, price per share (in dollars per share) | $ / shares   $ 2.009          
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares   $ 0.001          
v3.26.1
STOCKHOLDERS’ EQUITY - Level 3 Inputs Used In Valuation Models (Details)
Mar. 31, 2026
USD ($)
Series A Warrants, 6-Month Expiry  
Stock-Based Compensation [Line Items]  
Fair value $ 0.73
Series A Warrants, 5-Year Expiry  
Stock-Based Compensation [Line Items]  
Fair value 1.51
Common stock issuable upon exercise of Series B Warrants  
Stock-Based Compensation [Line Items]  
Fair value $ 1.29
Probability | Series A Warrants, 6-Month Expiry  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 0.975
Probability | Series A Warrants, 5-Year Expiry  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 0.025
Stock price | Series A Warrants, 6-Month Expiry  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 1.79
Stock price | Series A Warrants, 5-Year Expiry  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 1.79
Stock price | Common stock issuable upon exercise of Series B Warrants  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 1.79
Strike price | Series A Warrants, 6-Month Expiry  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 1.40
Strike price | Series A Warrants, 5-Year Expiry  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 1.40
Strike price | Common stock issuable upon exercise of Series B Warrants  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 1.40
Expected volatility | Series A Warrants, 6-Month Expiry  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 1.15
Expected volatility | Series A Warrants, 5-Year Expiry  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 1.15
Expected volatility | Common stock issuable upon exercise of Series B Warrants  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 1.15
Expected term in years | Series A Warrants, 6-Month Expiry  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 0.5
Expected term in years | Series A Warrants, 5-Year Expiry  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 5.0
Dividend rate | Series A Warrants, 6-Month Expiry  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 0
Dividend rate | Series A Warrants, 5-Year Expiry  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 0
Dividend rate | Common stock issuable upon exercise of Series B Warrants  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 0
Risk-free interest rate | Series A Warrants, 6-Month Expiry  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 0.0381
Risk-free interest rate | Series A Warrants, 5-Year Expiry  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 0.0375
Risk-free interest rate | Common stock issuable upon exercise of Series B Warrants  
Stock-Based Compensation [Line Items]  
Measurement input for outstanding warrants 0.0375
v3.26.1
STOCKHOLDERS’ EQUITY - Number of Warrants Outstanding, the Weighted Average Exercise Price, and the Aggregate Intrinsic Value (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2026
Dec. 31, 2025
Weighted Average Remaining Contractual Life in Years and Aggregate Intrinsic Value    
Weighted Average Exercise Price (in dollars per share) $ 1.09 $ 1.40
Aggregate Intrinsic Value (in thousands) $ 68,067 $ 55,221
March 2026 Private Placement    
Weighted Average Remaining Contractual Life in Years and Aggregate Intrinsic Value    
Weighted Average Exercise Price (in dollars per share)   $ 0.001
Aggregate Intrinsic Value (in thousands) $ 23,747  
Series A and B Warrants    
Series A and Series B Warrants    
Class of warrant outstanding, beginning balance (in shares) 67,342,325  
Series A Warrants exercised into common stock (in shares) (16,140,663)  
Series A Warrants exercised into Pre-Funded Warrants (in shares) (2,856,666)  
Class of warrant outstanding, ending balance (in shares) 48,344,996  
Pre-Funded Warrants    
Series A and Series B Warrants    
Series A Warrants exercised into Pre-Funded Warrants (in shares) (2,856,666)  
Class of warrant outstanding, ending balance (in shares) 13,558,376  
Weighted Average Remaining Contractual Life in Years and Aggregate Intrinsic Value    
Weighted Average Exercise Price (in dollars per share) $ 0.001  
Aggregate Intrinsic Value (in thousands) $ 6,339  
Pre-Funded Warrants | March 2026 Private Placement    
Series A and Series B Warrants    
Pre-Funded Warrants purchased in 2026 Private Placement (in shares) 10,701,710  
v3.26.1
STOCK-BASED COMPENSATION - Additional Information (Details) - USD ($)
3 Months Ended
Jan. 01, 2026
Jan. 01, 2025
Jan. 01, 2024
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
May 04, 2017
Stock-Based Compensation [Line Items]              
Stock-based compensation expense       $ 1,046,000 $ 1,284,000    
Options outstanding (in shares)       20,861,149   17,613,352  
Granted (in shares)       4,575,750      
Unrecognized stock based compensation       $ 13,500,000 $ 1,200,000    
Remaining average vesting period (in years)       2 years 10 months 13 days 2 years    
Stock options and RSUs              
Stock-Based Compensation [Line Items]              
Stock-based compensation expense       $ 800,000 $ 1,300,000    
Granted (in shares)       4,575,750 3,370,900    
Unvested stock options, outstanding (in shares)       9,136,687 8,299,628    
Performance-based Option Awards              
Stock-Based Compensation [Line Items]              
Stock-based compensation expense       $ 0 $ 0    
Options outstanding (in shares)       0 0    
Restricted Stock Units              
Stock-Based Compensation [Line Items]              
Stock options, vesting period (in years)       3 years      
Restricted stock units granted (in shares)       398,375 249,201    
Restricted stock units outstanding (in shares)       669,545      
2017 Equity Incentive Plan              
Stock-Based Compensation [Line Items]              
Number of company's common stock reserved for issuance under the plan (in shares)       7,410,779     3,052,059
Percentage increase, outstanding stock maximum       5.00%      
Number of additional shares reserved for issuance under the plan (in shares) 6,509,217            
Stock option granted, term (in years)       10 years      
Stock options, vesting period (in years)       4 years      
Share based compensation, exercisable period       90 days      
Share based compensation, exercisable period after death       18 months      
Share based compensation, exercisable period after disability       12 months      
2017 ESPP              
Stock-Based Compensation [Line Items]              
Number of company's common stock reserved for issuance under the plan (in shares)       173,005      
Number of additional shares reserved for issuance under the plan (in shares)   0 0        
Percentage of discount from market price on purchase date       15.00%      
Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan (in shares)       33,015 34,509    
Stock-based compensation expense       $ 9,000 $ 21,876    
Percentage increase, outstanding stock maximum       1.00%      
Number of additional shares authorized (in shares)       550,000      
2017 ESPP | Employee Stock              
Stock-Based Compensation [Line Items]              
Common stock, reserved for future issuance (in shares)             279,069
2014 Equity Incentive Plan              
Stock-Based Compensation [Line Items]              
Options outstanding (in shares)       638,844      
Share based compensation, exercisable period       30 days      
Share based compensation, exercisable period after death or disability       6 months      
v3.26.1
STOCK-BASED COMPENSATION - Schedule of Recognized Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Stock-Based Compensation [Line Items]    
Stock-based compensation expense $ 1,046 $ 1,284
Research and development    
Stock-Based Compensation [Line Items]    
Stock-based compensation expense 307 401
General and administrative    
Stock-Based Compensation [Line Items]    
Stock-based compensation expense $ 739 $ 883
v3.26.1
STOCK-BASED COMPENSATION - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Stock-Based Compensation [Line Items]    
Stock-based compensation expense $ 1,046 $ 1,284
Employee Stock Purchase Plan    
Stock-Based Compensation [Line Items]    
Stock-based compensation expense 10 21
Share Based Payment Arrangement, Option And RSU    
Stock-Based Compensation [Line Items]    
Stock-based compensation expense $ 1,036 $ 1,263
v3.26.1
STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Compute Fair Value of Options Granted (Details) - Employee Stock Option - $ / shares
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Stock-Based Compensation [Line Items]    
Volatility 99.57% 86.51%
Expected term in years 5 years 11 months 23 days 5 years 5 months 12 days
Dividend rate 0.00% 0.00%
Risk-free interest rate 3.71% 3.94%
Fair value of option on grant date (in dollars per share) $ 1.32 $ 0.41
v3.26.1
STOCK-BASED COMPENSATION - Schedule of Options Outstanding and Weighted Average Exercise Price (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2026
Dec. 31, 2025
Series A and Series B Warrants    
Options outstanding, beginning balance (in shares) 17,613,352  
Vested and exercisable, ending balance (in shares) 11,724,462 11,042,865
Granted (in shares) 4,575,750  
Exercised (in shares) (123,024)  
Forfeited or expired (in shares) (1,204,929)  
Options outstanding, ending balance (in shares) 20,861,149 17,613,352
Pre-Funded Warrants    
Options outstanding, beginning balance (in dollars per share) $ 2.68  
Vested and exercisable (in dollars per share) 3.13 $ 3.49
Granted (in dollars per share) 1.65  
Exercised (in dollars per share) 1.51  
Forfeited or expired (in dollars per share) 4.20  
Options outstanding, ending balance (in dollars per share) $ 2.42 $ 2.68
Weighted Average Remaining Contractual Life in Years and Aggregate Intrinsic Value    
Weighted Average Remaining Contractual Life in Years, Options outstanding 7 years 4 months 17 days 6 years 6 months 21 days
Weighted Average Remaining Contractual Life in Years, Vested and exercisable 5 years 11 months 1 day 5 years 3 months
Aggregate Intrinsic Value, Options outstanding $ 11,377,000 $ 5,332
Aggregate Intrinsic Value, Vested and exercisable $ 3,552 $ 1
v3.26.1
INCOME TAXES (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Tax Disclosure [Abstract]    
(Benefit) provision for income taxes $ 0 $ 0
v3.26.1
COMMITMENTS AND CONTINGENCIES (Details)
1 Months Ended 3 Months Ended
Jan. 31, 2026
USD ($)
May 31, 2023
USD ($)
Aug. 31, 2022
USD ($)
product
Dec. 31, 2021
USD ($)
Dec. 31, 2016
USD ($)
product
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2025
USD ($)
Loss Contingencies [Line Items]                  
Prepaid expenses and other current assets           $ 4,623,000     $ 4,733,000
Research and development           $ 11,181,000 $ 6,659,000    
Loss on fraudulent funds transfer               $ 1,800,000  
Gensaic, Inc                  
Loss Contingencies [Line Items]                  
Payments to acquire investment     $ 5,100,000            
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                  
Loss Contingencies [Line Items]                  
Advance written notice required to terminate agreement           90 days      
Northwestern University | License Agreement                  
Loss Contingencies [Line Items]                  
Upfront non-creditable one-time license issuance fee payment         $ 75,000        
Annual license maintenance fee payable         20,000        
Consideration payable for rights grant (up to)         $ 5,300,000        
Royalty obligation period         10 years        
Minimum number of product covered under license agreement | product         1        
AstraZeneca                  
Loss Contingencies [Line Items]                  
Upfront cash payment       $ 5,000,000.0          
Shares issued in license agreement       $ 7,300,000          
Days immediately preceding the execution date       30 days          
License agreement milestone payments (up to)       $ 203,000,000.0          
First payment due upon completion of first phase       $ 3,000,000.0          
Gensaic, Inc                  
Loss Contingencies [Line Items]                  
Remaining prepaid research $ 1,000,000.0                
Gensaic, Inc | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                  
Loss Contingencies [Line Items]                  
License agreement milestone payments (up to)     452,000,000.0            
Research plan and budget, expected costs   $ 3,500,000 $ 3,000,000.0            
Prepaid expenses and other current assets           $ 1,000,000.0     $ 1,000,000.0
Research and development           $ 0 $ 0    
Developmental milestone approvals, number of products (at least) | product     3            
v3.26.1
COLLABORATION AND LICENSE AGREEMENTS (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2025
Jun. 30, 2025
Feb. 28, 2025
Mar. 31, 2021
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Dec. 31, 2025
Oct. 31, 2023
Apr. 30, 2023
Mar. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Total revenue         $ 0 $ 130,000          
Common stock shares issued (in shares)         167,266,466   167,266,466 130,184,353      
Common stock, par value (in dollars per share)         $ 0.001   $ 0.001 $ 0.001      
Collaborative Arrangement, Co-promotion | Takeda Pharmaceutical Company Limited                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Upfront payment under royalty and termination agreement       $ 196,000,000.0              
Aggregate milestone payments       $ 660,000,000.0              
Percentage of potential royalties                 13.00%    
License agreement milestone payments (up to)                 $ 30,000,000.0    
Collaborative Arrangement, Co-promotion | Takeda Pharmaceutical Company Limited | Maximum                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Additional payment on sales percentage       20.00%              
Collaborative Arrangement, Co-promotion | Takeda Pharmaceutical Company Limited | Related Party                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Related party transaction expenses recognized         $ 0 0          
Total revenue         $ 0 $ 0          
Marinus License Agreement | Marinus Pharmaceuticals, Inc                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Common stock shares issued (in shares)                     123,255
Common stock, par value (in dollars per share)                     $ 0.001
Takeda Pharmaceutical Company Limited | Collaborative Arrangement, Co-promotion                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Agreement ownership share       50.00%              
Marinus Pharmaceuticals, Inc                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Sale of long-term investment     $ 70,000                
Marinus Pharmaceuticals, Inc | Marinus License Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Royalty expense $ 6,300,000 $ 7,000,000.0         $ 700,000        
Graviton Bioscience Corporation | Series A Preferred Stock                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Purchase of preferred stock                   $ 10,000,000.0  
v3.26.1
RELATED PARTY TRANSACTIONS (Details) - 2025 Private Placement - USD ($)
1 Months Ended 12 Months Ended
Mar. 24, 2026
Oct. 31, 2025
Dec. 31, 2025
Related Party Transaction [Line Items]      
Aggregate purchase price   $ 75,100,000  
Common stock issuable upon exercise of Series B Warrants      
Related Party Transaction [Line Items]      
Sale of stock (in shares)   57,722  
Common stock issuable upon exercise of Series B Warrants | Chief Executive Officer      
Related Party Transaction [Line Items]      
Sale of stock (in shares)     71
Series A Warrants      
Related Party Transaction [Line Items]      
Number of securities called by warrants or rights (in shares)   38,481,325  
Series A Warrants | Chief Executive Officer      
Related Party Transaction [Line Items]      
Number of securities called by warrants or rights (in shares)     47,333
Common stock issuable upon exercise of Series B Warrants      
Related Party Transaction [Line Items]      
Number of securities called by warrants or rights (in shares)   500  
Common stock issuable upon exercise of Series B Warrants | Chief Executive Officer      
Related Party Transaction [Line Items]      
Number of securities called by warrants or rights (in shares) 47,773   35,500
Aggregate purchase price $ 66,266   $ 99,000
v3.26.1
NET LOSS PER SHARE - Narrative (Details) - shares
Mar. 31, 2026
Dec. 31, 2025
Common stock issuable upon exercise of Series A Warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Preferred stock, shares outstanding (in shares) 0 0
v3.26.1
NET LOSS PER SHARE - Schedule of Basic and Diluted Earnings Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Series A Preferred Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Allocation of net loss - basic, Series A Preferred Stock $ 0 $ (177)
Allocation of net loss - diluted, Series A Preferred Stock $ 0 $ (177)
Weighted-average common shares outstanding, basic (in shares) 0 1,250
Weighted-average common shares outstanding, diluted (in shares) 0 1,250
Net loss per share, basic (in dollars per share) $ 0 $ (141.57)
Net loss per share, diluted (in dollars per share) $ 0 $ (141.57)
Common Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Allocation of net loss - basic, Common Stock $ (16,988) $ (10,058)
Allocation of net loss - diluted, Common Stock $ (16,988) $ (10,058)
Weighted-average common shares outstanding, basic (in shares) 136,171,393 71,045,265
Weighted-average common shares outstanding, diluted (in shares) 136,171,393 71,045,265
Net loss per share, basic (in dollars per share) $ (0.12) $ (0.14)
Net loss per share, diluted (in dollars per share) $ (0.12) $ (0.14)
v3.26.1
NET LOSS PER SHARE - Schedule of Computations of Diluted Weighted-Average Shares Outstanding (Details) - shares
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Stock options to purchase common stock (in shares) 50,066,694 85,375,757
Stock options to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Stock options to purchase common stock (in shares) 20,861,149 17,613,352
Common stock issuable upon exercise of Series A Warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Stock options to purchase common stock (in shares) 19,483,996 38,481,325
Common stock issuable upon exercise of Series B Warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Stock options to purchase common stock (in shares) 28,861,000 28,861,000
Unvested RSUs    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Stock options to purchase common stock (in shares) 669,545 420,080
v3.26.1
SEGMENT REPORTING - Narrative (Details)
3 Months Ended
Mar. 31, 2026
segment
Segment Reporting [Abstract]  
Number of operating segments 1
Number of reportable segments 1
v3.26.1
SEGMENT REPORTING - Schedule of Direct Expenses With Respect to Program Segments (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Revenue $ 0 $ 130
Total research and development expenses 11,181 6,659
Total general and administrative expenses 6,665 6,021
Total operating expenses 17,846 12,680
Operating loss (17,846) (12,550)
Other income (expense), net 858 2,315
Net loss (16,988) (10,235)
Reportable Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Revenue 0 130
Payroll and payroll-related expenses 1,924 1,837
Total direct program expenses 8,785 4,244
Other research and development expenses 472 578
Total research and development expenses 11,181 6,659
Payroll and payroll-related expenses 2,115 3,130
Legal and professional fees 2,771 1,451
General office expenses 1,779 1,440
Total general and administrative expenses 6,665 6,021
Total operating expenses 17,846 12,680
Operating loss (17,846) (12,550)
Other income (expense), net 858 2,315
Net loss (16,988) (10,235)
Reportable Segment | OV329    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total direct program expenses 5,463 859
Reportable Segment | KCC2 library    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total direct program expenses 1,914 2,778
Reportable Segment | OV4071    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total direct program expenses 982 0
Reportable Segment | OV888 (GV101)    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total direct program expenses 0 339
Reportable Segment | Other programs    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total direct program expenses $ 424 $ 268
v3.26.1
SEGMENT REPORTING - Schedule of Components of Other (Income) Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting [Abstract]    
Stock-based compensation expense $ 1,046 $ 1,284
Interest/accretion income on securities 737 491
Severance expense 0 435
Gain from recovery of fraudulent funds transfer 0 1,800
Depreciation and amortization $ 35 $ 141